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Toxin-antitoxin (TA) gene pairs have been identified in nearly all bacterial 
genomes sequenced to date and are thought to facilitate persistence and antibiotic 
tolerance. TA loci are classified into various types based upon the characteristics of 
their antitoxins, with those in type II expressing proteic antitoxins. Many toxins from type 
II modules are ribonucleases that maintain a PilT N-terminus (PIN) domain containing 
conserved amino acids considered essential for activity. The vapBC (virulence 
associated protein) TA system is the largest subfamily in this class and has been linked 
to pathogenesis of nontypeable Haemophilus influenzae (NTHi). This dissertation 
presents three studies investigating type II TA modules in NTHi. The first study 
determined the crystal structure of the VapBC-1 complex. Based on this structure, 
aspartate-to-asparagine and glutamate-to-glutamine mutations of four conserved 
residues in the PIN domain of VapC-1 were constructed, and the effects of these 
mutations on pathogenesis were tested ex vivo. A novel model system was designed 
that consisted of an NTHi ΔvapBC-1 strain complemented in cis with the toxin mutants 
in tandem with the wild-type antitoxin controlled by the vapBC-1 native promoter in 
single copy. This determined that a single mutation to a conserved amino acid in the 
PIN domain significantly reduced the survival of NTHi. The second study measured the 
induction of a type II antitoxin in trans and the induction of a type II toxin in cis with or 
 
 
without an E. coli arabinose permease in cis in the background of NTHi. A bioassay was 
then designed to investigate the ability of NTHi to transport arabinose, the molecule 
necessary to induce the araBAD genes. Lastly, a bioinformatics study was performed 
on 12 recently-sequenced clinical isolates of NTHi to determine the conservation of four 
vap operons. Seven strains maintained all four operons, the other five strains 
maintained three and the operons all shared significant sequence homology. These 
three studies provide insight into the importance of the type II TA loci in NTHi and due to 
their conservation and contribution to pathogenesis, these modules prove to be 
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Haemophilus influenzae was originally called Bacillus influenzae (or Pfeiffer’s 
bacillus) by bacteriologist Richard Pfeiffer when it was mistakenly identified as the 
causative agent of the 1889 influenza pandemic (1). It was not until the 1920s that the 
organism was named H. influenzae (2). It is a Gram-negative obligate commensal of the 
upper respiratory tract. H. influenzae is divided into two groups – encapsulated strains 
and un-encapsulated or nontypeable strains (NTHi). There are six capsular serotypes, 
a-f (3), whose capsular region (cap) all share the same organization (4-7). The cap 
locus is comprised of three regions – region I contains the bexDCBA genes which code 
for an ATP-driven polysaccharide export apparatus (8), region II contains serotype-
specific DNA which distinguishes the six serotypes from each other (9), and region III 
contains the hcsAB genes which facilitate transport of the capsular polysaccharide 





FIG 1 Representation of the cap locus in H. influenzae. The polysaccharide capsule in 
typeable H. influenzae is controlled by the cap locus for all six serotypes (a-f). Regions I 
and III are conserved among serotypes while region II encodes the genes responsible 
for the specific polysaccharide synthesis. Region II can vary in the number of genes 





were most often associated with invasive diseases such as meningitis, cellulitis, and 
septicemia, related to a high incidence of morbidity and mortality (11). However, since 
the approval of the first Hib conjugate vaccine in 1987, there has been a significant 
decrease in disease associated with Hib (12, 13).  
H. influenzae is a human-adapted commensal of the upper respiratory tract. 
Meningitis caused by Hib has significantly decreased in countries that routinely 
vaccinate against the bacterium. However, in developing countries it is estimated that 
meningitis affects 7-13 million children under the age of five annually (14). NTHi is the 
most common bacterial cause of chronic obstructive pulmonary disease (COPD), which 
according to the World Health Organization (WHO), is the third leading cause of death 
worldwide (15, 16). NTHi is also a leading cause of recurrent otitis media (OM) in the 
pediatric population (17). The financial implications of these three diseases is in the 
billions of dollars annually (18-20).   
Unfortunately, the Hib vaccine is not effective in preventing infections caused by 
NTHi because the conjugate vaccine links a carrier protein to the polyribosylribitol 
phosphate (PRP) capsule unique to Hib. Due to the absence of a capsule as well as the 
genetic diversity of NTHi (21, 22), a suitable vaccine candidate against infections 
caused by NTHi is not available. Consequently, NTHi infections have been on the rise 
since the implementation of the Hib vaccine. NTHi strains share a number of virulence 
factors such as lipooligosaccharide (LOS), IgA protease, biofilm formation, adhesions, 
and other surface structures; however, the heterogeneity of the species makes it 
increasingly difficult to develop a vaccine suitable against a large number of isolates 
(23).  Some of the outer membrane proteins that have been explored as potential 
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vaccine candidates include: P1, P2, P4, P6, Tbp1, Tbp2, and protein D (24). Two 
vaccines seemed to provide positive results: a ketodeoxyoctanoate (KDO) based 
glycoconjugate vaccine elicits a response from the monoclonal antibody 6E4 and binds 
to KDO (25). However, susceptible strains would have to express the KDO epitope in 
high levels, and in a small study of 33 NTHi strains, only 36% of the isolates were killed 
by the anti-KDO antibody (25). Another potential candidate is the protein D conjugate 
vaccine. In a clinical trial of nearly 5,000 infants, protective efficacy was reported in 36% 
of infants vaccinated with the 10-valent pneumococcal H. influenzae protein D 
conjugate vaccine (PHiD-CV) (26). However, a number of studies measured carriage 
rates after children were fully vaccinated with the PHiD-CV and found no change in the 
rates (27-29). 
While a vaccine would be ideal in the race to prevent diseases caused by NTHi, 
the antigenic variations among gene products in this species may just be too great for 
preparation of an effective vaccine. However, exploiting toxin-antitoxin (TA) modules is 
a novel way to treat disease and infections caused by NTHi. TA loci were first identified 
on plasmids as modules that aided in plasmid maintenance and stability by mediating 
the killing of plasmid-free cells and thereby ensuring stable plasmid inheritance (30, 31). 
Following the advent of whole genome sequencing, TAs were found to be maintained in 
the chromosomes of numerous Gram-negative and Gram-positive bacterial genera as 
well as in the Archaea (32-34). Chromosomally-located TAs have been implicated as 
important metabolic regulators in many human pathogens, including Escherichia coli, 
nontypeable Haemophilus influenzae (NTHi), Mycobacterium tuberculosis, and 
Staphylococcus aureus (35-38). Stressful environmental conditions, such as nutrient 
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limitation, heat, pH, and oxidative stress from the host immune response or antibiotic 
therapy (39-42), initiate degradation of the labile antitoxin via bacterial proteases such 
as Lon and ClpXP (43, 44). After the antitoxin is degraded, the toxin is free to inhibit 
essential cellular processes, such as ATP and protein synthesis, DNA replication, 
peptidoglycan synthesis, and cell division (45-49), resulting in growth arrest and 
facilitating a persister state.  
TA modules are operons typically organized with the antitoxin located directly 
upstream of the toxin. Six different TA families have been identified and characterized 
by the nature of the antitoxin. In type I and type III systems, the antitoxin is an RNA. The 
type I antitoxin is antisense RNA that binds the toxin mRNA under normal cellular 
conditions, inhibiting its translation (50). Following degradation of the type I antitoxin, 
the toxin is translated and depolarizes the cell membrane, thereby inhibiting ATP 
synthesis (50, 51). In the type III TA loci, the antitoxin is a pseudoknot RNA that binds to 
the protein toxin and prevents it from cleaving RNA (52, 53). Type II, IV, V, and VI 
systems all contain protein antitoxins. In type II systems, both the antitoxin and toxin are 
proteins that form a non-toxic complex upon translation (54). Many toxins of the type II 
TA modules have been characterized as ribonucleases (46, 55). Type IV systems are 
unique in that the antitoxin inhibits toxin activity by interacting directly with the targets of 
the toxin, which are cytoskeletal proteins necessary for proper cell division (49, 56). The 
only type V TA locus described to date is ghoST, in which the antitoxin inhibits the 
activity of the toxin by cleaving its mRNA (57). There is one identified type VI locus 
currently, designated as socAB. In this module, the antitoxin SocA does not inhibit the 
activity of the SocB toxin directly, but rather guides it to the protease ClpXP (58). When 
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SocB is not degraded by ClpXP, it binds to DnaN and inhibits DNA replication and 
elongation (58). Free-living prokaryotes tend to have more TA loci than obligate 
intracellular microorganisms, and pathogenic bacteria often have more TA loci than their 
non-pathogenic relatives (59). Maintaining numerous TA loci in their genomes may 
increase the ability of microorganisms to rapidly respond to stresses in their 
microenvironments, and there is growing interest in studying the contributions of these 
systems to microbial pathogenesis and persistence.  
Type II TA loci contribute significantly to the survival and virulence of NTHi during 
infection (36, 60). With this in mind, this dissertation highlights the use of the newly 
solved crystal structure of VapBC-1 from NTHi to study the highly conserved PilT N-
terminal (PIN) (61) domain and the implications it has on NTHi survivability in a recently 
published human infection model. A novel assay was designed in the background of 
NTHi to study the growth arrest and growth recovery of the type II toxin and antitoxin 
proteins utilizing IPTG and arabinose-inducible promoters. Lastly, 12 clinical isolates of 
NTHi were sequenced and the sequences were used to investigate the conservation 
and organization of four conserved type II TA loci maintained in H. influenzae strains. 
The conservation of these TA loci in NTHi makes them novel candidates for 
antimicrobial therapy. 





CRYSTAL STRUCTURE OF VAPBC-1 FROM NONTYPEABLE HAEMOPHILUS 
INFLUENZAE AND THE EFFECT OF PIN DOMAIN MUTATIONS ON SURVIVAL 
DURING INFECTION 
This chapter is published, and is reprinted here with permission: 
Molinaro AL, Kashipathy MM, Lovell S, Battaile KP, Coussens NP, Shen M, Daines DA. 
2019. Crystal Structure of VapBC-1 from Nontypeable Haemophilus influenzae and the 




Type II modules are currently the best characterized TAs and the vapBC (virulence 
associated protein) system is the largest subfamily in this class, with VapB being the 
proteic antitoxin and VapC the ribonuclease toxin. The VapB antitoxin has two roles in 
the VapBC system: a region near its C-terminus binds to and neutralizes the toxin, while 
its N-terminus binds DNA and increases the TA complex stability in auto-regulating 
transcription of its cognate operon (Fig. 2) (62). The VapC toxin contains a conserved 
PIN domain that is crucial for its activity (61). While it has been shown that some VapC 
homologues are able to target specific RNA in bacterial cells (55, 63, 64), it is important 
to note that a VapC toxin has not yet been co-crystallized with its specific RNA target (62).  
NTHi maintains two vapBC modules in its chromosome, designated as vapBC-1 
and vapBC-2. It has been previously shown that the vapBC-1 locus significantly increases 
survival during infection, both in vivo and ex vivo (36). Despite low primary sequence 
homology among the VapC toxins from different microorganisms, the PIN domain is 
ubiquitous and characterized by highly conserved acidic, polar, and hydrophobic residues 
in the active site (62, 65). The VapBC-1 crystal structure was solved with the assistance 
of collaborators from the Protein Structure Laboratory at the University of Kansas and the 
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Advanced Photon Source at Argonne National Laboratory. Based on the VapBC-1 crystal 
structure, directed mutations were introduced to four PIN domain residues and evaluated 
the resulting mutant’s protein-protein interactions, effects on the growth of E. coli, and 
ability to survive during infections of primary human tissues ex vivo. The results show that 
some of the mutations in the PIN domain of the VapC-1 toxin were associated with 
decreased toxicity in E. coli, but the mutants retained the ability to homodimerize and to 
heterodimerize with the wild-type cognate antitoxin, VapB-1. A new system was designed 
and constructed to quantify the effects of these mutations on NTHi survival during 
infections of primary human tissues ex vivo. Any mutation to a conserved amino acid in 
the PIN domain significantly decreased the number of survivors compared to that of the 








FIG 2 Model of TA locus function and inhibition of the toxin with a small molecule. Under 
stressful conditions, the antitoxin is degraded, freeing the toxin to cleave mRNA, 
resulting in bacterial growth arrest. Small molecules that inhibit the activity of the toxin 
VapC-1 would prevent growth arrest, thereby facilitating the complete clearance of a 
bacterial infection when used in conjunction with antibiotic therapy. This figure is 





Structural analysis of VapBC-1. Although VapBC structures from other 
organisms have been determined (66), the structure of VapBC-1 from NTHi has not been 
reported. Therefore, the crystal structure of VapBC-1 was determined from a 
polyhistidine-tagged construct that allowed the VapB-1 antitoxin to be co-expressed with 
the VapC-1 toxin. The primary sequences of the purified toxin and antitoxin used for 





(A) VapB-1 and (B) VapC-1. The underlined residues are from the pET24b cloning 
vector.  
  
FIG 3 Primary sequence of the VapBC-1 complex used for crystallization screening. 
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The overall structure of NTHi VapC-1 adopts an -β- sandwich fold in which five 
central β-strands are flanked by two -helical regions typically observed for PIN-like 
domains (Fig. 4A). Subunits of VapC-1 form a dimer in which the hydrophobic surfaces 
of helices 3 and 5 are positioned approximately 10 Å from one another (Fig. 5A). The 
active site residues D6, E43, D99 and E120, depicted as spheres in Fig. 5A, are 
conserved amongst various VapC species and adopt a similar spatial arrangement 
relative to previously determined structures. The main network of hydrogen bonds is 
formed between dimer subunits through residues Y81 in helix 5 and N97, N98 and W101 
of helix 6 (Fig. 5B). An additional hydrogen bond is present between E75 of subunit B 
and Y41 in helix 3 of subunit A. The reciprocal interaction, E75 in subunit A with Y41 of 
subunit B, is not observed as the side chains are positioned 5 Å apart. Thus, this hydrogen 
bond interaction is not likely a critical interaction between dimer subunits. Similar to 
previously determined structures (62, 67), the VapC-1 dimer has an interface area of 
1,024 Å2, a solvation free energy gain from dimer formation (ΔGint) of -21.6 kcal/mol and 
13% of the accessible surface area buried as determined with PISA (68). As noted above, 
there is minimal hydrogen bonding between the dimer subunits and no salt bridge 
interactions are present.  
The VapC-1 dimer adopts a similar arrangement compared to structures from other 
organisms (Fig. 6). Comparison of the NTHi VapC-1 dimer with homologous structures, 
identified from a PDBeFold search (69) yielded RMS deviations between C-atoms of 
1.85 Å (251 residues, VapC D98N from Shigella flexneri, PDB 5ECD) (70), 1.85 Å (253 




FIG 4 Structure of the H. influenzae VapC-1 monomer subunit. (A) Colored by 
secondary structure with -helices (green) and β-sheets (magenta). (B) Primary and 
secondary structural elements of VapC-1. Conserved active site residues are indicated 





FIG 5 Structure of the H. influenzae VapC-1 dimer showing subunits A and B in 
magenta and cyan, respectively. (A) View along the 2-fold axis of the dimer. Helices that        
form the interacting surfaces between subunits are indicated. Conserved active site 
residues are rendered as spheres. Note that E120 (chain A) was partially disordered so 
all of the side chain atoms were not modeled. (B) Hydrogen bond interactions (dashed 




from Rickettsia felis in complex with DNA, PDB 3ZVK) (72). The main difference is 
observed in helix 2 which is moved further away from helix 1 in the NTHi VapC-1 dimer 
as noted in panel A of Fig. 6. As shown below, this relative difference in the position of 
helices 1-2 is necessary to accommodate VapB-1 binding. Slightly lower RMS 
deviations were observed when comparing single subunits and superposition with VapC-
1 (subunit A) yielded the following: 5ECD (subunit A, 1.48 Å, 126 residues), 3TND 
(subunit C, 1.37 Å, 129 residues) and 3ZVK (subunit A, 1.54 Å, 131 residues). The main 
conformational differences occur in the relative positions of helices 1-2 as was 
observed for superposition of the dimers noted above. 
The VapB-1 portion of the NTHi VapBC-1 complex could be modeled from M1 to 
P72 (subunit C) and M1 to D69 (subunit D). The overall structure of VapB-1 consists of a 
ribbon-helix-helix motif in which the four β-sheets of the N-terminus dimerize with another 
subunit to form a β-barrel type architecture (Fig. 7). As determined using PISA (68), 
extensive hydrogen bonding and salt bridge interactions are present between the dimer 
subunits (27 and 11 respectively) which forms an interface area of 1,662 Å2 and a 
solvation free energy gain of -17.0 kcal/mol. Notably, 25% of the accessible surface area 
is buried to form the dimer interface. The C-terminus contains a long stretch of flexible 
residues occupied by two -helices that bind to the VapC-1 toxin forming a 1:1 interaction 
between VapB-1 and VapC-1 subunits. A similar architecture is observed for other VapBC 
structures, such as VapBC from R. felis in complex with DNA (PDB 3ZVK). The 
dimerization core regions are quite similar. However, the VapC-1 binding region of the C-
terminus adopts a markedly different orientation relative to the VapB-1 β-barrel dimer 




FIG 6 Comparison of the H. influenzae VapC-1 dimer (magenta/cyan) with the VapC 
dimer from homologous structures. (A) VapC D98N (coral) from Shigella flexneri (PDB          
5ECD); (B) VapBC (gold) from Shigella flexneri (PDB 3TND); (C) VapBC (green) from 





FIG 7 Structure of the H. influenzae VapB-1 dimer showing subunits C (gold) and D 
(blue). Secondary structure elements annotated for subunit C. (A) Perpendicular view; 
(B) view along the β-barrel axis; (C) primary and secondary structural elements of 
VapB-1.   
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quaternary structural arrangements that produce higher order oligomers (62). 
Although the toxin:antitoxin form commonly observed consists of 1:1 interactions 
between subunits, the quaternary arrangement resulting from the binding of NTHi VapB-
1 to VapC-1 in this structure appears to be unique. As shown in Fig. 8A, the asymmetric 
unit consists of a VapB-1 and VapC-1 dimer in which the C-terminal helices of VapB-1 
(subunit C) occupy a cleft formed by 1-4 of VapC-1 (subunit A). Subunit B of VapC-1 
forms a similar interaction with VapB-1 (subunit D). However, this interaction is with a 
VapB-1 molecule related by crystallographic symmetry (Fig. 8B) and creates tightly 
packed pairs of VapB-1 and VapC-1 dimers (Fig. 8C). This arrangement results in a row 
of alternating VapB-1 and VapC-1 dimers.   
As noted above, the C-terminal tails of VapB-1 are positioned within a cleft formed 
by 1-4 of a VapC-1 dimer. Specifically, the C-terminal tail spanning P41-P72 (subunit 
C) and P41-D69 (subunit D) of VapB-1 (Fig. 9A) position the -helices within a 
complementary cleft of VapC-1 subunits A and B respectively (Fig. 9B). The binding 
interface between VapB-1 and VapC-1 is 1,385 Å2 with a solvation free energy gain of      
-21.8 kcal/mol. The majority of the hydrogen bond and salt bridge interactions occur at 
the C-terminus of VapB-1 spanning residues A66 to L70 (Fig. 10). Notably, R67 of VapB-
1 interacts with E43 and D99 of VapC-1, which are conserved catalytic residues along 
with D6 and E120, amongst various VapC species (73). Similar interactions were 
observed for the S. flexneri VapBC structure (PDB 3TND), suggesting a similar mode of 
VapC-1 inhibition. Additional hydrogen bond interactions are observed between G55 and 





FIG 8 Structure of VapBC-1 with VapB-1 subunits C/D (gold/blue) and VapC-1 subunits 
A/B (magenta/cyan). (A) Asymmetric unit showing the positioning of the C-terminal tail 
of VapB-1 (subunit C) occupying the cleft formed by 1-4 of VapC-1 (subunit A); (B) 
asymmetric unit with an extra VapB-1 dimer related by crystallographic symmetry 




FIG 9 Binding of VapB-1 to VapC-1. (A) Zoomed-in view of Fig. 5B showing the binding 
of the C-terminal tail of VapB-1 subunit C residues P41to P72 (gold) and subunit D 
residues P41-D69 (blue) bound to the VapC-1 dimer; (B) electrostatic surface of VapC-1 
subunit A showing the binding of the C-terminal -helices of VapB-1 (P41-P72, gold) 





FIG 10 Hydrogen bond interactions between the C-terminal end of VapB-1 subunit C 




Protein-protein interactions in vivo. Proteins encoded by type II TA modules 
form nontoxic heterocomplexes of the antitoxin and toxin homodimers under normal 
growth conditions in vivo (66). In order to examine antitoxin and toxin homodimer 
formation and heterodimerization, a bacterial LexA-based system (74) was employed. 
The LexA repressor consists of two domains, a DNA-binding domain (DBD) and a 
dimerization domain. The DBD can function as a transcriptional repressor only in 
dimeric form. Other domains can be fused in-frame to the DBD and will restore the 
repressor's function only if they interact (75). If the fused proteins interact, the lacZ 
reporter gene is repressed, reducing beta-galactosidase activity, which is quantitated 
biochemically as dimensionless Miller units (76). Strong protein-protein interactions 
result in minimal beta-galactosidase activity, whereas weak interactions result in 
significant activity. 
This system was applied to evaluate the ability of VapC-1 single and double site-
directed mutants to interact with the wild-type VapB-1 antitoxin (heterodimerization) as 
well as with themselves (homodimerization) in vivo. The homodimerization of the wild-
type VapC-1 toxin was not evaluated due to its substantial toxicity when overexpressed 
from a high copy number plasmid. Table 1 shows that the VapC-1 mutants retained the 
ability to homodimerize with comparative strengths of interaction of E120Q > D6N > E43Q 
D99N > E43Q > D99N > D6N D99N. Mutant or wild-type VapC-1 toxins could 
heterodimerize with wild-type VapB-1, at relative levels of D6N > D6N D99N > E43Q 
D99N > E120Q > WT > E43Q > D99N (Table 2). 
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TABLE 1 Homodimerization of VapC-1 mutants  
 Homodimerizationa of LexA DBD 
fusion in SU101 (Miller units) 
Construct Avg ± SD 
pSR658 (control) 1302.6 78.2 
VapC-1 D6N 38.5 12.9 
VapC-1 D99N  59.5 9.4 
VapC-1 D6N D99N  148.3 24.8 
VapC-1 E43Q  55.5 9.8 
VapC-1 E43Q D99N 39.2 2.2 
VapC-1 E120Q 27.6 8.4 
aThe homodimerization of the wild-type VapC-1 toxin was not evaluated due to its 
substantial toxicity when overexpressed in high copy. 
 
 
TABLE 2 Heterodimerization of VapC-1 mutants with the wild-type VapB-1 antitoxin 
 Heterodimerization of LexA 
DBD fusions in SU202 (Miller 
Units) 
Construct Avg ± SD 
Control vectors 1813.4 130.0 
VapC-1 D6N  37.9 11.5 
VapC-1 D99N  360.5 30.6 
VapC-1 D6N D99N  56.0 6.0 
VapC-1 E43Q 202.2 18.9 
VapC-1 E43Q D99N 113.3 5.5 
VapC-1 E120Q 167.3 11.6 




VapC-1 activity in vivo. A growth-recovery assay was used to evaluate VapC-1 
activity in E. coli. Mutant or wild-type VapC-1 toxins were individually cloned under the 
control of the PBAD promoter and induced with 3.3 mM (0.05% wt/vol) L-arabinose (77). 
The wild-type VapB-1 antitoxin was under the control of the Ptrc promoter and its 
expression was induced with 0.5 mM IPTG (78). Thus, VapC-1 and VapB-1 could be 
induced either independently or simultaneously from compatible plasmids that are co-
transformed and expressed in the same E. coli strain, LMG194. To initiate the assay, a 
culture in early growth phase was split and treated with either: (i) media only, (ii) 
arabinose-only, (iii) IPTG-only, or (iv) both arabinose and IPTG. Typically, significant 
growth arrest occurs at approximately 70 min after wild-type VapC-1 was induced, but 
this was not observed if the antitoxin is expressed alone (Fig. 11A, red and green 
symbols, respectively). If VapB-1 and VapC-1 were co-induced, the antitoxin inhibited the 
toxin ribonuclease activity and growth was similar to the non-induced control (Fig. 11A, 
purple and blue symbols, respectively). The results of experiments with the VapC-1 
mutants are presented in Fig. 11B-G. Significantly attenuated growth was observed upon 
induction of VapC-1 in strains with the wild-type, D99N and E120Q mutant toxins (red 
symbols in Fig. 11A, C, and G, respectively), compared to the growth observed when 
VapB-1 was co-induced (purple diamonds). However, the VapC-1 D6N, D6N D99N, 
E43Q, and E43Q D99N mutants did not cause significant growth arrest when induced in 





FIG 11 E. coli growth-recovery assays with inducible wild-type or mutant VapC-1 toxins. 
(A) Non-induced E. coli growth (measured by absorbance at 595 nm) or growth 
following induction of wild-type (WT) VapC-1, VapB-1, or both WT VapC-1 and VapB-1. 
(B to G) Similar growth experiments were performed with the VapC-1 D6N (B), D99N 
(C), D6N D99N (D), E43Q (E), E43Q D99N (F), and E120Q (G) mutants. All data are 
plotted as mean ± SD of the result of three biological replicates in triplicate. Statistical 
comparisons of growth following WT or mutant VapC-1 inductions against the 
corresponding non-induced controls were made using the repeated-measures ANOVA. 
The significance of the results were as follows: VapC-1 WT P < 0.0001 (A); D6N mutant 
P = 0.21 (B); D99N mutant P = 0.0015 (C); D6N D99N mutant P = 0.15 (D); E43Q 




FIG 11 Continued.  
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Construction of an in cis ectopic system to study TA modules. The growth 
recovery assay in E. coli strain LMG194 is a valuable tool to evaluate the effects of toxin 
and antitoxin expression. However, the antitoxin and toxin proteins are cloned into 
separate multi-copy vectors to allow independent expression and are controlled by 
artificial promoters. Therefore, the assay does not allow either expression via the native 
transcriptional regulation of the locus or the characterization of a mutant locus in single 
copy on the chromosome. To evaluate these aspects, a novel system was developed that 
consisted of the native vapBC-1 promoter controlling an operon containing the wild-type 
vapB-1 gene followed by either the wild-type or each mutant vapC-1 gene (Fig. 12). This 
system mimics the natural sequential arrangement and copy number of the operon. The 
module is flanked by homologous regions of the metE pseudogene from NTHi strain 86-
028NP (NTHI_RS09270, an authentic frameshift resulting in a deletion of over 100 amino 
acids) which targets the reconstructed TA locus to a chromosomal region that is not in 
use. Briefly, fusions are amplified by PCR, used to transform NTHi, and are homologously 
recombined into the chromosome at the NTHI_RS09270 pseudogene site in single copy. 
NTHi is an obligate human parasite with natural deletions in many genes involving 
metabolism. Since it scavenges a number of essential molecules from its host, this results 
in the requirement to supplement growth media in vitro but not in vivo or ex vivo (79-81). 
The well-characterized 86-028NP ΔvapBC-1 strain (36) was chosen as the background 
to analyze each tandem fusion to eliminate contributions by the wild-type vapBC-1 locus. 
This novel approach is the most biologically relevant system currently available to study 
the effects of TA locus mutants in the background of NTHi. 
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To ensure that the in cis mutant modules had no effect on the replication of strains, 
the growth of the reconstructed wild-type, vapBC-1 mutants, and the parent strain 86-
028NP ΔvapBC-1 was measured over 7 h. There were no significant differences in growth 
among the strains (data not shown), supporting the use of this model to investigate 





FIG 12 NTHi_RS09270 delivery vector for single-copy in cis expression of cloned 
genes. This construct targets the metE pseudogene in strain 86-028NP. The native  
vapBC-1 promoter controls either the wild-type vapBC-1 operon or an engineered 





Effect of VapC-1 mutations on survival of NTHi in primary human tissues. 
The EpiAirway model (AIR 100 ABF, MatTek, Ashland, MA, USA), which consists of 
antibiotic-free primary human respiratory epithelial tissue at the air-liquid interface, was 
used to evaluate the impact of VapC-1 mutations on NTHi survival during infections. After 
co-culturing the in cis complemented strains with EpiAirway tissues in antibiotic-free 
media for 48 h, the tissues were treated with 100 µg/ml gentamicin for 90 min to kill any 
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NTHi not internalized, as this antibiotic does not enter the tissues. The surviving 
internalized bacteria were recovered, diluted and plated for viable colony counts. This 
experiment was performed with n = 6 tissues originating from at least two different 
EpiAirway kits. The survival of all strains containing VapC-1 mutants were significantly 
reduced compared to the strain containing wild-type toxin (Fig. 13). The survival of the 
parent strain, 86-028NP ΔvapBC-1, was also significantly decreased, as previously 





FIG 13 Number of viable CFU/milliliter of NTHi in cis-complemented mutants or the wild-
type operon in primary human tissues at the air-liquid interface. EpiAirway tissues were 
infected at ~ 1.0 x 104 CFU per insert with either the 86-028NP ΔvapBC-1 deletion 
strain, the 86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (wild-type) 
strain, the 86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (D6N) strain, 
the 86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (D99N) strain, the 
86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (D6N D99N) strain, the 
86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (E43Q) strain, the 86-
028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (E43Q D99N) strain, the 86-
028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (E120Q) strain, or the 86-
028NP ΔvapBC-1 parent strain. At 48 h after infection, gentamicin-resistant bacteria 
were harvested for colony counts. Data are expressed as the mean ± SD of six 
biological replicates in quadruplicate. All in cis mutants and the parent strain were 
significantly attenuated for survival compared to the strain carrying the wild-type VapC-1 





The VapC-1 toxin of NTHi is an efficient and highly active ribonuclease, and the 
vapBC-1 locus is crucial for survival during infection, both ex vivo in primary human 
tissues, and in vivo in the chinchilla model of acute otitis media (36). The PIN domain of 
VapC homologues has been implicated in the binding and cleavage of RNA substrates 
(70) and many acidic residues in this domain are highly conserved (73). Other studies 
have evaluated various mutations to the PIN domain (82, 83), and it was previously 
demonstrated that the VapC-1 D99N mutant had significantly reduced ribonuclease 
activity, while retaining the ability to bind VapB-1 (84).  
The NTHi VapBC-1 structure provides insight into heterodimeric interactions and 
enables comparisons with VapBC complexes from other organisms. Overall, the VapBC-
1 homodimer subunits are similar to other reported VapB and VapC structures, adopting 
similar protein:protein interactions with the VapB C-terminal helices occupying clefts 
within VapC dimers. The homodimer subunits in VapBC complexes often form higher 
order oligomers such as heterotetramers, heterohexamers and heteroctamers (62). 
Interestingly, the VapBC-1 complex does not adopt any of these higher order quaternary 
structures but instead forms a unique linear array of alternating VapB and VapC dimers.  
Based on the crystal structure of VapBC-1, two highly conserved aspartate and 
two glutamate residues in the toxin PIN domain were mutated to their beta-amino 
derivatives, asparagine and glutamine. Analyses of these mutant constructs indicated 
decreased ribonuclease activity in vivo measured by growth-recovery assays, and 
decreased survival during ex vivo infections of primary human tissues compared to the 
wild-type toxin when expressed in the background of NTHi using a novel single-copy in 
30 
 
cis system. This study also found that the effect of these mutations were not necessarily 
additive, as although a VapC-1 D99N mutant was significantly attenuated when 
overexpressed in E. coli growth-recovery assays, a double D6N D99N mutation was not. 
Interestingly, all VapC-1 mutants were able to strongly homodimerize as well as to bind 
wild-type VapB-1, suggesting that the module’s quaternary structure is somewhat 
decoupled from the enzymatic activity of the toxin.  
The results reported here support the notion that VapBC-1 (and TA modules in 
general) have evolved a number of mechanisms to maintain their activity and that their 
presence confers a significant advantage to the microorganism. Many studies have linked 
TA modules to the survival of bacterial pathogens in host tissues (36, 85-89). Achieving 
and maintaining persistence during an infection is central for both successfully evading 
the immune response and for nonspecific antibiotic tolerance, leading to a pathogen’s 
survival of clinical therapy. This characteristic can substantially contribute to recurrent or 
chronic infections and implicates TA modules as therapeutic targets. Indeed, when the 
effects of the toxin mutations on NTHi survival inside primary human respiratory tissues 
ex vivo were tested, it was found that any perturbation of the acidic residues in the 
conserved PIN domain negatively affected survival compared to the wild-type toxin under 
the same conditions. These data suggest that targeting any of these individual residues 
in the toxin could potentially result in significantly decreasing the survival of NTHi during 




MATERIALS AND METHODS 
Bacterial strains and culture conditions. The bacterial strains and plasmids 
used in these studies are listed in Table 3. E. coli strains were grown in LB broth or agar 
with or without 100 µg/mL ampicillin, 250 µg/ mL erythromycin, 20 µg/mL 
chloramphenicol, 30 µg/mL of kanamycin, or 12 µg/mL tetracycline, as required. NTHi 
strains were grown in brain heart infusion broth or agar supplemented with 10 μg/mL 
heme-histidine and 10 μg/mL β-NAD (sBHI), or on chocolate agar with 5 U/mL bacitracin. 
NTHi were routinely cultured at 37 °C with 5% CO2. To construct the ectopic strains, 
transformants were selected on chocolate agar plates with 5 μg/mL erythromycin, and 
single colonies were passaged for 3 days on selection plates before being confirmed by 
DNA sequencing of PCR amplified purified genomic DNA.  
Site-directed mutagenesis of VapC-1. VapC-1 D6N and D99N mutants cloned 
in tandem with a wild-type VapB-1 in the vector pET24b (Millipore Sigma, Burlington, MA 
USA) were previously described (84). These constructs were used as templates for 
plasmid expression sets. Synthetic constructs of VapC-1 with E43Q, E120Q, and E43Q 
D99N mutations were generated in tandem with wild-type VapB-1 by Eurofins (Eurofins 
Genomics, Louisville, KY USA). The VapC-1 D6N D99N construct, also in tandem with 
the wild-type VapB-1, was produced by Genscript (Piscataway, NJ USA). Each construct 
was confirmed by DNA sequencing (Eurofins Genomics, Louisville, KY USA) following 




TABLE 3 Bacteria, plasmids and primers used in this study 
Strains Description Source 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
Laboratory 
collection 
LMG194 F- ΔlacX74 galE thi rpsL ΔphoA (PvuII) Δara714 
leu::Tn10 
Invitrogen 








86-028NP ΔvapBC-1 Strain 86-028NP with the vapBC-1 locus deleted (36) 
Plasmids Description Source 
pBAD33 Highly regulated expression vector (77) 
pET24b Regulated expression vector with His tag Novagen 
pBluescript SK(+) Cloning vector (36) 
pSR658 WT LexA DBD fusion vector (74) 
pSR659 Mutant LexA DBD fusion vector (74) 
pSR660 WT LexA DBD fusion vector (74) 
pSR661 Mutant LexA DBD fusion vector (74) 
pDD686 vapBC-1 in pET24b  (46)  
pDD757 vapBC-1 (vapC-1 D6N) in pET24b  Unpublished 
pDD758 vapBC-1 (vapC-1 D99N) in pET24b (84) 
pDD866 vapB-1 in pSR658 (36) 
pDD935 vapB-1 in pTrcHisA Unpublished 
pDD946 vapC-1 in pBAD33  Unpublished 
pDD1058 5’ end of NTHI_RS09270 in pBluescript SK(+) This work 
pDD1063 3’ end of NTHI_RS09270 in pDD1058 This work 
pDD1118 vapBC-1 (vapC-1 D6N D99N) in pUC57 Genscript 
pDD1119 vapC-1 D6N D99N in pBAD33 This work 
pDD1120 vapC-1 D99N in pSR658 This work 
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TABLE 3 Continued   
Plasmids Description Source 
pDD1123 vapC-1 D99N in pSR659 This work 
pDD1126 vapC-1 D6N in pSR661 This work 
pDD1128 vapC-1 D6N D99N in pSR661 This work 
pDD1132 vapC-1 D6N in pBAD33 This work 
pDD1133 vapC-1 D99N in pBAD33 This work 
pDD1140 NTHI_RS09270-targeted delivery vector This work 
pDD1150 vapC-1 in pSR659 This work 
pDD1152 vapC-1 D6N in pET24b This work 
pDD1153 vapC-1 D99N in pET24b This work 
pDD1154 vapC-1 D6N D99N in pET24b This work 
pDD1155 pDD1140 with the native vapBC-1 promoter This work 
pDD1159 pDD1155 with vapB-1vapC-1 D6N  This work 
pDD1160 pDD1155 with vapB-1vapC-1 D99N This work 
pDD1161 pDD1155 with vapB-1vapC-1 D6N D99N  This work 
pDD1165 vapBC-1 (vapC-1 E43Q) in pCR2.1 Eurofins 
pDD1166 vapBC-1 (vapC-1 E120Q) in pCR2.1 Eurofins 
pDD1167 pDD1155 with vapB-1vapC-1 E43Q  This work 
pDD1168 pDD1155 with vapB-1vapC-1 E120Q  This work 
pDD1169 pDD1155 with vapB-1vapC-1 wild-type This work 
pDD1170 vapC-1 E43Q in pSR658 This work 
pDD1173 vapC-1 E43Q in pET24b This work 
pDD1174 vapC-1 E120Q in pBAD33 This work 
pDD1175 vapC-1 E43Q in pBAD33 This work 
pDD1177 vapC-1 E120Q in pSR658 This work 
pDD1178 vapC-1 E43Q in pSR659 This work 
pDD1179 vapC-1 E120Q in pSR659 This work 
pDD1194 vapC-1 E43Q D99N in pBAD33 This work 
pDD1196 vapC-1 E43Q D99N in pBAD/Myc-HisA This work 
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TABLE 3 Continued   
Plasmids Description Source 
pDD1199 vapC-1 E43Q D99N in pSR658 This work 
pDD1200 vapC-1 E43Q D99N in pSR659 This work 
pDD1204 pDD1155 with vapB-1vapC-1 E43Q D99N  This work 
Primers Description Source 
D6NFor [Phos]AACACCAATATCATTATTTATTTAATG IDT 
D6NRev [Phos]TAACATATAAATCATAAATTTTCTCG IDT 
321LexFor GAGGGAGCTCATGCTTACTAAAGTG IDT 
321LexRev AACAGGTACCTCATAAATTTTCTCG IDT 
322LexFor GAGAGAGCTCATGATTTATATGTTAG IDT 
322LexRev TCAGGGTACCCTATTTTGTCCAATCTTGCC IDT 
pETD6NC1SacFor AAAAGAGCTCTATGATTTATATGTTAAACACC Eurofins  
322Rev TCAGAAGCTTCTATTTTGTCCAATCTTGCC IDT 
pBAD86C1SacFor TTACGAGCTCAGGAGCGAGAAAATTTATG Eurofins  
XLacIFor GTCATCTAGAAAACGCGCGAGGCAGC Eurofins  
XHisRev TATTTGTCTAGAGGCAGTTCCCTACTCTCG Eurofins  
86C1NdeD6NFor AAACATATGATTTATATGTTAAACAC Eurofins  
VapCXhoRev GAATCTCGAGTTTTGTCCAATCTTGCC Eurofins 
86C1NdeFor AAAACATATGATTTATATGTTAGAC Eurofins  
PermCSpeFor AAATACTAGTAACACACACGCCATTCC Eurofins  
ErmCSpeRev GTTAACTAGTGCAGTTATGCATCC Eurofins  
BC1PromBamFor ACTAGGATCCATCATTTACTCATTGACTTGC Eurofins  
BC1PromNdeRev TAAGCATATGTACCCTCTCGTATATAC Eurofins  
86B1NdeFor GGTACATATGCTTACTAAAGTG Eurofins  
2009-1SacFor TGCCGAGCTCGCAGGTAAGATGTCG Eurofins  
2009-1XbaRev AAAATCTAGAGATGCACGTGCAACC Eurofins  
2009-2XhoFor AAAACTCGAGGCTTGCATCTAATGC Eurofins  




Purification of VapC-1 for crystallization studies. To overexpress VapBC-1 
for purification, pDD686 in BL21(DE3) (46) was grown to logarithmic phase at 37 °C 
with shaking, induced for 18 h with 1 mM IPTG at 26 °C and harvested at 2,500 x g into 
pellets from 25 mL aliquots. After one freeze-thaw cycle, VapBC-1 was isolated in 
accordance with the MagneHis protein purification system (Promega, Madison, WI 
USA) with the following exceptions: the lysis solution was 1X BugBuster protein 
extraction reagent (Millipore Sigma, Burlington, MA USA) with 100 mM HEPES pH 7.2, 
300 mM NaCl, 1X ProteCEASE-50 (EDTA-free), and 2 µL/mL RNase-free DNase 
(Thermo Fisher Scientific, Waltman, MA USA); the wash buffer contained 100 mM 
HEPES  pH 7.2 , 300 mM NaCl and 20 mM imidazole, and the elution buffer contained 
100 mM HEPES  pH 7.2, 300 mM NaCl and 500 mM imidazole. 1 µg of purified VapBC-
1 was separated on a Bolt precast 4-12% polyacrylamide gel and analyzed via Western 
blot using the iBlot and iBind system (Thermo Fisher Scientific, Waltman, MA, USA). 
The nitrocellulose blot was probed with a monoclonal anti-His tag primary antibody 
(THE anti-His, Genscript, Piscataway, NJ USA), goat anti-mouse IgG-HRP secondary 
antibody (Genscript, Piscataway, NJ USA), detected with SuperSignal West Dura 
chemiluminescence substrate (Thermo Fisher Scientific, Waltman, MA, USA) and 
imaged on a UVP BioSpectrum 815 (UVP LLC., Upland, CA USA). 
Crystallization and data collection. A purified preparation of the NTHi VapBC-1 
protein complex was concentrated to 20 mg/mL in 20 mM NaCl, 10 mM HEPES pH 7.2 
for crystallization screening. All crystallization experiments were set up using an NT8 drop 
setting robot (Formulatrix Inc.) and UVXPO MRC (Molecular Dimensions) sitting drop 
vapor diffusion plates at 18 °C. 100 nL of protein and 100 nL of crystallization solution 
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were dispensed and equilibrated against 50 µL of the latter. Crystals approximately 100 
µm long that displayed a needle morphology were observed within one week from the 
Proplex screen (Molecular Dimensions) condition C3 (20% [wt/vol] PEG 4000, 100 mM 
sodium acetate pH 5.0, 200 mM ammonium acetate). A cryoprotectant solution composed 
of 80% crystallization solution and 20% (vol/vol) PEG 200 was dispensed (2 uL) onto the 
drop, crystals were harvested with a cryoloop immediately and stored in liquid nitrogen. 
X-ray diffraction data were collected at the Advanced Photon Source beamline 17-ID 
using a Dectris Pilatus 6M pixel array detector.   
Structure solution and refinement. Intensities were integrated using XDS (90, 
91) via Autoproc (92) and the Laue class analysis and data scaling, using two data sets 
to increase the multiplicity, were performed with Aimless (93) which indicated that the 
crystals belong to the mmm Laue class. Structure solution was conducted by molecular 
replacement with Morda (94) to place a VapC-1 dimer using Shigella flexneri VapC (PDB 
5ECD) as the template and the top solution was obtained in the space group P212121. 
The VapC-1 coordinates from Morda were input as a fixed solution into Phaser (95) and 
a VapB monomer from the Rickettsia felis VapBC structure (PDB 3ZVK) was used as a 
search model. The final solution from Phaser consisted of a VapB-1 and VapC-1 dimer in 
the asymmetric unit and the model was improved by automated building with Arp/wARP 
(96). Further refinement and manual model building were conducted with Phenix (97) and 
Coot (98), respectively. Disordered side chains were truncated to the point for which 
electron density could be observed. Structure validation was conducted with Molprobity 
(99) and figures were prepared using the CCP4MG package (100). Structure 
superposition was carried out with GESAMT (101). Crystallographic data are provided in 
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Table 4. Coordinates and structure factors were deposited to the worldwide Protein Data 




TABLE 4 Crystallographic data for VapBC-1 
Parameter Value(s) for VapBC-1 
Data Collection  
Unit-cell parameters (Å, o) a=43.88, b=57.32, c=175.75 
Space group P212121 
Resolution (Å)a 48.01-2.20 (2.28-2.20) 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Observed reflections 303,859 
Unique reflections 23,388 
<I/(I)>a 10.9 (2.1) 
Completeness (%)a 100 (100) 
Multiplicitya 13.0 (13.7) 
Rmerge (%)
a,b 16.8 (161.3) 
Rmeas (%)
a,d 17.5 (167.7) 
Rpim (%)
a,d 4.9 (45.2) 
CC1/2 
a,e 0.998 (0.784) 
Refinement  
Resolution (Å)a 48.01-2.20 
Reflections (working/test)a 22,146/1,166 
Rfactor / Rfree (%)
a,c 18.6/23.4 
No. of atoms (VapB/VapC-
1/Water) 
1,085 / 2,103 / 58 
Model Quality  
R.m.s deviations   
Bond lengths (Å) 0.009 
Bond angles (o) 0.981 
Average B-factor (Å2)  




TABLE 4 Continued 
Parameter Value(s) for VapBC-1 





(maximum likelihood) (Å) 
0.24 
Ramachandran Plot   
Most favored (%) 96.8 
Additionally allowed (%) 3.0 
 
aValues in parenthesis are for the highest resolution shell. 
bRmerge = hkli |Ii(hkl) - <I(hkl)>| / hkli Ii(hkl), where Ii(hkl) is the intensity measured for 
the ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.  
cRfactor = hkl ||Fobs (hkl) | - |Fcalc (hkl) || / hkl |Fobs (hkl)|; Rfree is calculated in an identical 
manner using 5% of randomly selected reflections that were not included in the 
refinement. 
dRmeas, redundancy-independent (multiplicity-weighted) Rmerge (93, 102);  Rpim, precision-
indicating (multiplicity-weighted) Rmerge (103).  
eCC1/2 is the correlation coefficient of the mean intensities between two random half-




Cloning and protein-protein interactions of VapC-1 mutants. The VapC-1 
D99N, E43Q, E43Q D99N, and E120Q mutants were cloned by amplifying the vapC-1 
D99N gene from pDD758, the vapC-1 E43Q gene from pDD1165, the vapC-1 E43Q 
D99N gene from pDD1196, or the vapC-1 E120Q gene from pDD1166 using high-fidelity 
Phusion Flash DNA Polymerase (Thermo Fisher Scientific, Waltham, MA USA) and the 
primers 322LexFor and 322LexRev. The PCR products, pSR658, and pSR659 were 
digested with SacI and KpnI prior to ligation, resulting in pDD1120, pDD1123, pDD1170, 
pDD1178 pDD1199, pDD1200, pDD1177, and pDD1179. VapC-1 D6N and D6N D99N 
were cloned by amplifying the vapC-1 D6N gene from pDD757 and the vapC-1 D6N D99N 
gene from pDD1118, using high-fidelity Phusion Flash DNA Polymerase with 
pETD6NC1SacFor and 322LexRev primers. The PCR products, pSR660, and pSR661 
were digested with SacI and KpnI prior to ligation, resulting in pDD1125, pDD1126, 
pDD1129, and pDD1128. The wild-type VapC-1 toxin was cloned into pSR659 with the 
above method from NTHi strain 86-028NP genomic DNA (pDD1150). All clones were 
confirmed by DNA sequencing. The pSR659 or pSR661 constructs were co-transformed 
with pDD866 into SU202 to perform heterodimerization assays. The pSR658 or pSR660 
constructs were individually transformed into SU101 for homodimerization assays.  
Expression of the LexA fusions were induced by IPTG and if the fusion proteins 
interacted, a competent repressor was formed in the reporter strain that could bind the 
operator site and decrease transcription of the lacZ reporter gene. This resulted in a 
measurable decrease in β-galactosidase activity compared to a strain carrying the control 
unfused vectors. However, because β-galactosidase is a long-lived enzyme, the reporter 
strains were grown overnight in the presence of 1 mM IPTG so that any enzyme 
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expressed prior to the LexA chimera induction is degraded. This strategy results in a more 
reliable and accurate quantification of homodimerization and heterodimerization. 
Following overnight incubation on LB agar plates with 1 mM IPTG and appropriate 
antibiotics, reporter strains carrying the control vectors (pSR658 and pSR659 or pSR660 
and pSR661) (75) or the LexA DBD fusions were inoculated and grown to an optical 
density at 600 nm (OD600) of ~0.5 in LB broth with 1 mM IPTG and appropriate antibiotics. 
Protein-protein interactions were quantified by β-galactosidase activity assays and 
compared to the activity of the reporter strain carrying the unfused vectors, which has the 
highest activity due to the lack of repressor formation. The algorithm for quantifying β-
galactosidase activity was: [OD420-(1.75 x OD550)/(t x v x OD600)] x 1000, where t is time 
of reaction development in minutes and v is volume of sample in milliliters (76). This 
equation allows for the normalization of different culture densities for comparison 
purposes. 
Cloning and growth-recovery assays with VapC-1. To clone wild-type and 
mutant VapC-1 genes for the growth-recovery assays, the wild-type vapC-1 gene was 
amplified from NTHi strain 86-028NP genomic DNA, the vapC-1 D6N gene was amplified 
from pDD757, the vapC-1 D99N gene was amplified from pDD758, the vapC-1 D6N D99N 
gene was amplified from pDD1118, the vapC-1 E43Q gene was amplified from pDD1165, 
the vapC-1 E43Q D99N gene was amplified from a synthetic gene produced by Eurofins, 
and the vapC-1 E120Q gene was amplified from pDD1166  using high-fidelity Phusion 
Flash DNA polymerase with pBAD86C1SacFor and 322Rev primers. The PCR products 
and pBAD33 were digested with SacI and HindIII prior to ligation, resulting in pDD946, 
pDD1132, pDD1133, pDD1119, pDD1175 pDD1194, and pDD1174. The forward primer 
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was designed to include the putative Shine-Dalgarno sequence for VapC-1. The vapB-1 
gene was amplified from 86-028NP genomic DNA using high-fidelity Phusion Flash DNA 
Polymerase with 321LexFor and 321LexRev primers. After digestion with SacI and KpnI 
the PCR fragment was ligated into pTrcHisA, resulting in pDD935. All clones were verified 
by DNA sequencing. Wild-type vapC-1 and each of the six mutants were co-transformed 
with pDD935 into E. coli strain LMG194. 
To perform the growth-recovery assays, strains were grown at 37 °C to early log 
phase (OD600 of ~0.2 - 0.3) in LB broth with 20 µg/mL chloramphenicol and 100 µg/mL 
ampicillin before being diluted in a 1:1 (vol:vol) ratio to a final volume of 150 microliters of 
media in a 96-well CorningTM FalconTM polystyrene microplate (Corning, Corning, NY, 
USA) containing LB broth with 20 µg/mL chloramphenicol and 100 µg/mL ampicillin, with 
or without 1 mM IPTG, 6.6 mM (0.1% wt/vol) arabinose, or both. The final induction 
concentrations were 0.5 mM IPTG and 3.3 mM (0.05% wt/vol) arabinose. The plate was 
covered with a gas permeable membrane, loaded into a Multiskan FC incubating plate 
reader (Thermo Fisher Scientific, Waltham, MA USA), and incubated at 37 °C with a 
shaking protocol of 5 s on and 5 s off with measurements taken every 10 min at OD595 for 
190 min. Each assay included three biological replicates with three technical replicates.  
Construction of the in cis delivery system and reconstituted NTHi strains. 
Based on a previously published ectopic delivery vector in NTHi (106), the metE 
pseudogene in the chromosome of strain 86-028NP (NTHI_RS09270) was targeted as 
the site for gene delivery and single-copy expression in cis. The delivery vector was 
constructed by amplifying 843 bp of the 5’ end of NTHI_RS09270 from 86-028NP 
genomic DNA using high-fidelity Phusion Flash DNA polymerase with 2009-1SacFor and 
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2009-1XbaRev primers and ligating the product into pBluescript SK+ digested with SacI 
and XbaI, resulting in pDD1058. The second homologous region of 767 bp of the 3’ end 
of NTHI_RS09270 was amplified from 86-028NP genomic DNA using high-fidelity 
Phusion Flash DNA polymerase with 2009-2XhoFor and 2009-2KpnRev primers and 
ligated into pDD1058 cut with XhoI and KpnI, resulting in pDD1063. The last step was 
amplifying a erythromycin resistance cassette from pEJ18 (107) with PermCSpeFor and 
ErmCSpeRev primers and ligating into pDD1063 cut with SpeI, resulting in the delivery 
vector, pDD1140. The native vapBC-1 promoter from 86-028NP was cloned into the 
multiple cloning site of the delivery vector using the primers BC1PromBamFor and 
BC1PromNdeRev. The reverse primer contains an engineered NdeI site (CATATG) in 
which the ATG of the restriction site (underlined) serves as the start codon for the fused 
vapBC-1 genes. This allowed us to clone all constructs with their native transcriptional 
regulation and organization. The vapBC-1 promoter was ligated to pDD1140 cut with 
BamHI and EcoRV, resulting in pDD1155. Because the vapC-1 mutants are in tandem 
with the wild-type vapB-1 gene, each was cloned into pDD1155 for delivery into the 86-
028NP chromosome. The vapBC-1 D6N locus was amplified from pDD757, vapBC-1 
D99N was amplified from pDD758, vapBC-1 D6N D99N was amplified from pDD1118, 
vapBC-1 E43Q was amplified from pDD1165, vapBC-1 E43Q D99N was amplified from 
a synthetic gene produced by Eurofins, vapBC-1 E120Q was amplified from pDD1166, 
and wild-type vapBC-1 was amplified from pDD686 using high-fidelity Phusion Flash DNA 
polymerase with 86B1NdeFor and 322Rev primers. Each amplicon was ligated to 
pDD1155 digested with NdeI and HindIII, resulting in pDD1159, pDD1160, pDD1161, 
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pDD1167, pDD1204, pDD1168, and pDD1169. This resulted in vapBC-1 with the desired 
mutations in vapC-1 under the control of its native promoter (Fig. 12).    
The strains of NTHi 86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-
1 with wild-type vapC-1 and the six mutants were constructed by homologous 
recombination into the chromosome of 86-028NP ΔvapBC-1 by PCR products containing 
both the flanking regions of NTHI_RS09270 and each promoter::tandem clone using MIV 
transformation (81). After selection on chocolate agar with 5 µg/mL erythromycin, a single 
colony of each transformant was passaged three times on antibiotic-containing plates. 
DNA sequencing of PCR-amplified genomic DNA preparations confirmed each correct 
strain. 
To ensure the in cis fusions did not affect the growth dynamics of NTHi, strains 
were grown to early log phase (OD600 of ~0.2 - 0.3) in sBHI broth before dilution into a 
96-well CorningTM FalconTM polystyrene microplate, and absorbance was measured 
following the same protocol as the growth-recovery assays over the course of 7 h. Each 
growth assay included three biological replicates with three technical replicates. 
NTHi infections of primary human tissues. EpiAirwayTM tissues (AIR-100-ABF, 
MatTek, Ashland, MA USA) were maintained, inoculated, and harvested as previously 
described (108) with the following exception: inserts were inoculated with approximately 
25 µl 1.0 x 104 CFU/mL bacterial suspension of the desired strain. Inserts were cocultured 
with the parent, wild-type or mutant strains for 48 h before harvesting and quantification 
by counting viable colonies from a plated dilution series on chocolate agar plates. 
Statistical analyses. Differences between means were determined using the 
Student’s t-test. Differences among multiple-group treatments were determined by the 
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repeated measures ANOVA or two-tailed ANOVA as appropriate using GraphPad Prism 
8.0.1 (GraphPad Software, La Jolla, CA USA). A p value of <0.05 was considered 
statistically significant.  
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USE OF THE L-ARABINOSE-INDUCIBLE ESCHERICHIA COLI ARABAD 
PROMOTER AND THE ARAC REGULATOR IN HAEMOPHILUS INFLUENZAE 
INTRODUCTION 
The discovery of inducible promoters to express genes has provided scientists with 
valuable tools to study gene expression. There are a wide variety of promoters with 
various regulators and induction methods available; however, the Ptrc (78), Plac (109-111), 
Ptac (111-113), PT7 (114), and PBAD (77) promoters are among the more popular 
expression systems. The PBAD expression vectors are extremely useful due to the tight 
regulation of the promoter via the regulatory gene, araC, the fast induction rate, and the 
ability to modulate the level of gene expression (77).   
The arabinose system has been studied extensively in E. coli and is composed of 
two independent transport systems (araE and araFGH), a set of metabolism genes known 
as the araBAD operon, and the regulatory gene, araC. The product of araE is a low-
affinity membrane protein that uses the electrochemical potential to transport arabinose 
into the cell (115, 116). The araFGH operon is a second high-affinity arabinose 
transporter belonging to the ATP-binding cassette (ABC) transporter family (117, 118). 
AraF is the arabinose-binding protein located in the periplasm (119), AraG binds ATP, 
and AraH is a membrane-associated protein involved in arabinose transport into the cell 
(117, 120). The araBAD operon converts L-arabinose to D-xylulose-phosphate, part of 
the pentose phosphate pathway, for use by bacteria in central metabolism (121). AraC is 
the regulatory protein of the arabinose system (122, 123). It positively regulates the 
promoters of araBAD, araE, and araFGH in the presence of arabinose (124); it negatively 
regulates the araBAD promoter in the absence of arabinose, and it negatively regulates 
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its own promoter in the presence and absence of arabinose (125). Two mechanisms 
describe the regulatory functions of the arabinose-specific AraC protein:  DNA looping 
(126, 127) and the light-switch mechanism (128, 129). In DNA looping, a protein or protein 
complex binds to two different sites of DNA causing it to create a loop (130). This looping 
decreases the concentration of the regulator, for example AraC, while still repressing 
gene expression. Conversely, the light-switch mechanism facilitates positions and 
orientations of the regulator protein(s) that favors DNA looping (131). When the regulator 
protein is in one position, DNA looping occurs and when the interaction changes, the loop 
can be broken to initiation transcription, simulating the on and off function of a light-switch. 
AraC functions as a homodimer. Each monomer has two domains connected by a flexible 
linker:  a dimerization domain that binds arabinose and a DNA-binding domain (Fig. 14). 
In the absence of arabinose, AraC binds to araO2 (O2) and araI (I1) causing the DNA to 
bend, creating a loop (126, 127). Meanwhile, the N-terminal arm extends from the 
arabinose-binding domain to the C-terminal DNA-binding domain, keeping the arabinose 
binding site exposed for arabinose when it becomes available (132). When arabinose 
arabinose is present, it sits in the arabinose-binding domain making it energetically 
favorable for the N-terminal arms to fold over the pocket and bind to the dimerization 
domains (129). When the arms release from the DNA-binding domains, it is energetically 
favorable for AraC to bind to adjacent I1 and I2 half-sites, providing space for RNA 
polymerase to bind to the PBAD promoter to initiate transcription (133, 134). The full 
induction of the arabinose genes requires AraC as well as the catabolite activator protein 




FIG 14 Regulation of the PBAD promoter by AraC. AraC is a homodimer. The C-terminal  
DNA binding domains bind to the O2 and I1 sites when arabinose is not present. This 
energetically favorable binding causes DNA to form a loop and inhibits RNA polymerase 
from binding to the PBAD and PC promoters. The N-terminal dimerization domains have 
arabinose-binding pockets. When arabinose binds, the N-terminal arm which was bound 
to the DNA binding domain folds over the arabinose-binding domain in a process called 
the light-switch mechanism. This facilitates a conformation change in the AraC 
homodimer and the DNA-binding domain that was bound to the O2 site folds over to 
bind to the I2 site. The DNA loop is released and RNA polymerase can now bind to the 
PBAD and PC promoters to facilitate transcription. This image is reproduced from 
reference 132 describing the history and mechanisms of AraC.  
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operator sites (Fig. 14) and stimulate the transcription of the araBAD operon (77, 135). 
Induction of the arabinose genes is inhibited by glucose levels because glucose reduces 
levels of cAMP by inhibiting adenylate cyclase.  
The expression system was originally designed for use in E. coli (77). However, 
the need to achieve high levels of gene expression, particularly of toxic gene products, 
has enticed scientists to expand the practical nature of the arabinose system into other 
bacterial species. Scientists have utilized the PBAD promoter and the araC regulator for 
routine cloning and gene expression to facilitate protein purification, analyze protein 
function, and study complex cellular physiological properties in the following species: 
Salmonella typhimurium (136), Agrobacterium tumefaciens (137), Corynebacterium 
glutamicum (138), Xanthomonas campestris pv. phaseoli (139), Pseudomonas 
aeruginosa (140), Vibrio cholerae (141), and Burkholderia cepacia (142).  
Previous studies have found the PBAD expression vectors to be extremely useful to 
study the ribonuclease toxin from type II TA loci. A growth recovery assay which utilized 
the plasmid pBAD33 (77) allowed induction of gene expression by arabinose to evaluate 
ribonuclease activity of VapC-1 mutants from NTHi in E. coli LMG194 (143).  
While it is common to utilize E. coli to study genes expressed in other bacterial 
species, in this study a novel assay was designed in the background of NTHi to test both 
the transport of arabinose and the ability of this molecule to regulate the expression of TA 
proteins in cis. Ideally, to study arabinose induction, a bacterial strain should be able to 
transport but not degrade arabinose, so that the molecule remains available to induce the 
PBAD promoter. An extensive BLAST search of NTHi genomes did not reveal genes that 
were homologous to known arabinose transport proteins and catabolic enzymes (144). In 
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this study, two novel NTHi delivery vectors were constructed: one that carried an araC 
gene with a PBAD::vapD expression cassette, and another that delivers an arabinose 
permease into the NTHi chromosome. Both genes were inducible by arabinose. These 
were used to transform an NTHi strain with a deletion of the TA locus vapXD (R2866 
ΔvapXD). Because the cassettes were flanked by DNA regions homologous to a target 
site on the chromosome and included an antibiotic marker (Fig. 16 and 17), they were 
recombined at the desired site following transformation and identification was facilitated 
by antibiotic selection followed by DNA sequencing of the in cis cassette. Using this novel 
design, the ability of the araC PBAD::vapD fusion to recombine into the NTHi chromosome 
at the site of a naturally-occurring pseudogene was evaluated. Then, one of two E. coli 
arabinose permease cassettes (comprised of either araE or araFGH) was targeted to 
another non-utilized site on the chromosome, a partial bacteriophage terminase gene. 
Upon successful homologous recombination of the toxin only, or the toxin with one of the 
two arabinose permease cassettes, expression of the toxin VapD with or without an 
arabinose permease was induced. Likewise, the ability of each permease to transport 
arabinose when expressed in NTHi was compared. A bioassay was then designed to 
measure the amount of arabinose uptake by NTHi by detecting the amount of arabinose 
left in the media after NTHi growth (hereinafter called conditioned media). This bioassay 
uses the expression of a green fluorescent protein (GFP) gene under the control of the 
PBAD promoter from the plasmid pGLO (Bio-Rad, Hercules, CA) in E. coli strain LMG194 
which is inducible by arabinose. First, it was demonstrated that arabinose could modulate 
GFP expression in chemically defined media using a dose-response control curve.  
Subsequently, this bioassay was used to measure the arabinose remaining in conditioned 
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media following NTHi growth at mid-log phase and also at stationary phase to determine 
whether 1) NTHi could transport arabinose across its membrane, and 2) whether the 





Growth dynamics of R2866 and the ΔvapXD mutant strain. To induce the 
expression of the toxin VapD and antitoxin VapX in the background of NTHi, it was 
necessary to create a vapXD deletion mutant to prevent crosstalk. The entire vapXD 
operon was deleted in R2866 by replacing the locus with a chloramphenicol resistance 
cassette. Following confirmation of deletion by PCR characterization of genomic DNA 
using various flanking primers, growth curves were performed to determine if the deletion 
had an effect on replication compared to the parent strain. No significant difference in the 
growth dynamics between the two strains was observed in sBHI (Fig. 15) and in glucose 
free DM with 10mM sodium pyruvate (data not shown).  
Construction of two in cis ectopic systems to study type II TA protein 
induction and arabinose permease function in NTHi. Use of a growth-recovery assay 
in the background of E. coli LMG194 to study the activity of NTHi VapC-1 mutants under 
the control of the PBAD promoter in trans was previously reported (143). While this is an 
excellent tool, this study sought to create an assay in the background of NTHi to study 
the function of the TA toxin VapD in cis to mimic the single copy toxin gene in the 
chromosome. In addition, this study also sought to investigate whether the addition of an 
E. coli arabinose permease in cis would increase arabinose transport across the NTHi 
membrane.  
 To evaluate these aspects, two novel systems were developed. The first contained 
both the arabinose operon regulatory gene, araC and the PBAD promoter controlling the 
type II toxin, vapD (Fig. 16). This system mimicked the normal copy number of the gene 




FIG 15 Growth dynamic comparisons between R2866 and ΔvapXD deletion mutant 
strains in sBHI. Strains were grown in a 96-well plate at 35°C with shaking. Data are 
expressed as the mean + SD of three biological replicates in triplicate. No significant 
difference was found between the growth of the parent strain, R2866 and the ΔvapXD 








FIG 16 R2866_RS09695 delivery vector for single-copy in cis expression of cloned 
genes. (A) The construct targets the metH pseudogene in strain R2866; (B) contains 




FIG 17 R2866_RS04985 delivery vector for single-copy in cis expression of cloned 
genes. (A) This construct targets the large subunit of the PBSX phage terminase gene 
in strain R2866; (B) contains the araE gene; (C) contains the araFGH operon cloned 
into pDD1230 under the control of their own promoters and are induced by arabinose. 
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flanked by homologous regions of the metH pseudogene from the NTHi strain R2866 
(R2866_RS09695), which targets the araC PBAD::vapD cassette to a chromosomal 
region that is not in use. Briefly, cassettes were amplified by PCR, used to transform 
NTHi, and were homologously recombined into the chromosome at the 
R2866_RS09695 pseudogene site in single copy. An R2866 ΔvapXD deletion strain 
was constructed as the background to analyze vapD induction to eliminate contributions 
by the wild-type vapXD locus. The second cassette targeted either the low-affinity 
arabinose permease gene, araE, or the high-affinity arabinose operon, araFGH into the 
large subunit of the PBSX phage terminase gene (R2866_RS04985) (Fig. 17), which 
was another region not utilized in NTHi. This novel approach resulted in a more 
biologically relevant system to study the induction of type II ribonuclease toxins under 
the control of the artificially-inducible PBAD promoter and to determine whether the 
addition of an E. coli arabinose permease increased arabinose transport in the 
background of NTHi.  
NTHi growth recovery assay. Traditionally, the toxin proteins of TA modules 
induce varying levels of growth arrest, whereas the antitoxins usually do not. Therefore, 
the NTHi-based growth recovery assay was designed with the toxin in single copy in cis 
and the antitoxin in multicopy in trans. The antitoxin, vapX, was evaluated in trans under 
the control of the Ptrc promoter and its expression was induced with 1 mM IPTG (isopropyl-
β-ᴅ-thiogalactopyranoside) (145, 146). The toxin, vapD, was evaluated in cis under the 
control of the PBAD promoter and was induced with 2.64 mM (0.04% wt/vol) arabinose 
(77) with or without either the low-affinity arabinose permease, araE, or the high-affinity 
arabinose permease, araFGH in cis (Fig. 18A to C). Thus, VapX and VapD could be 
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induced either independently or simultaneously while also comparing the effectiveness of 
an arabinose permease.  
To initiate the assay, a culture in early growth phase was split and treated with 
either: (i) media only, (ii) arabinose only, (iii) IPTG only, or (iv) both arabinose and IPTG. 
The results of the experiments with vapD in cis with or without either arabinose permease 
in cis induced with arabinose and vapX in trans induced with IPTG are presented in Fig. 
18A to C. VapD, from NTHi strain 86-028NP, is a ribonuclease toxin (36), and was 
induced in single copy in the background of NTHi to measure growth arrest. No significant 
growth arrest was observed when vapD in cis was induced in vivo with or without the 
addition of araE or araFGH (Fig. 18A to 18C, red symbols). 
Modulation of expression of GFP in glucose-free defined media. One of the 
advantages of using the PBAD promoter is the ability to modulate gene expression by 
varying the arabinose concentration in the media (77). In that context, it is believed that 
this is the first time an arabinose uptake and utilization system in NTHi defined media has 
been tested (147). The pGLO (pBAD-GFPuv (148)) plasmid was utilized because the 
reporter gene, GFP, is under the control of the PBAD promoter and therefore is inducible 
by arabinose. Arabinose in dose-response concentrations was used to induced pGLO in 
E. coli LMG194, using glucose-free defined media with 10 mM sodium pyruvate. Glucose-
free media was used because glucose reduces levels of cAMP by inhibiting adenylate 
cyclase which reduces CAP and therefore reduces induction of the arabinose genes as 
previously described in the introduction. Therefore, using glucose-free media 
supplemented with sodium pyruvate can increase the transcription of the araBAD operon 
while still providing NTHi with a suitable carbon source. Relative fluorescence units per 
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cell (RFU/cell) was calculated from GFP expression measured for each concentration of 
arabinose (Fig. 19). This experiment shows that arabinose in glucose-free defined media 
with 10 mM sodium pyruvate can modulate the expression of pGLO in LMG194 (Fig. 19). 
All treatments were compared and found to be statistically significant using one-way 
ANOVA.         
Transport of arabinose in NTHi. Since the level of expression of GFP from the 
plasmid pGLO induced in E. coli LMG194 reflected the amount of arabinose in the media 
(Fig. 19), this characteristic was used as a bioassay to determine the concentration of 
arabinose left in conditioned media after NTHi growth. The control was defined media 
with arabinose that was treated identically to the conditioned media, but without NTHi. If 
the amount of arabinose left in the conditioned media resembled the control media without 
bacteria, then it would indicate NTHi did not transport arabinose into the cell. Likewise, if 
the amount of arabinose left in the conditioned media was lower than in the control media 
without cells, then it would suggest NTHi could transport arabinose from the media into 
the cell. Finally, if the amount of arabinose left in the conditioned media from the strains 
with one of the arabinose permeases in cis was lower than in the conditioned media from 
strains with vapD only, then it could be due to increased arabinose transport by the 
permease.   
Conditioned media was obtained by inducing the following strains with 2.64 mM 
(0.04% wt/vol) arabinose: R2866 ΔvapXD RS09695::araC PBAD::vapD, R2866 ΔvapXD 
RS09695::araC PBAD::vapD RS04985::ParaE::araE, and R2866 ΔvapXD RS09695::araC 
PBAD::vapD RS04985::ParaFGH::araFGH and growing each to mid-log phase (approximate 
OD600 of 0.4) and to stationary phase (approximate OD600 of 1.3). Two growth phases 
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were chosen to determine if arabinose transport was affected by metabolism and/or cell 
growth in NTHi. The control was media treated with 2.64 mM (0.04% wt/vol) arabinose 
with no bacteria. The RFU/cell for the control and for each sample of conditioned media 
was calculated. The RFU/cell of the control was not significantly different from the 
conditioned media collected during mid-log or stationary phase for all three strains 
determined by the one-way ANOVA (Fig. 20). This result indicates that 1) arabinose 
cannot cross the membrane of NTHi, and 2) that the addition of the arabinose permease 
gene, araE, or the arabinose permease operon, araFGH from E. coli were not 




FIG 18 NTHi growth recovery assays in glucose-free defined media with 10 mM sodium 
pyruvate. NTHi growth-recovery assays with inducible VapX in trans and VapD in cis. 
(A) Without an arabinose permease; (B) with araE in cis; (C) with araFGH in cis. Non-
induced NTHi growth (measured by absorbance at 595 nm) or growth following 
induction of VapD, VapX, or both VapD and VapX. All data are plotted as the mean ± 
SD of three biological replicates in triplicate. There was no statistical significance among 




FIG 19 Modulation of GFP expression from the plasmid pGLO in E.coli LMG194. pGLO 
in E. coli LMG194 was treated with arabinose in four 10-fold dilutions or without 
arabinose. The relative fluorescence unit (RFU) per cell was calculated by dividing the 
total RFU by the number of cells (determined by the final OD595) per arabinose 
treatment group. The fluorescence of the negative control (media alone) was subtracted 
from each value. Data are expressed as the mean + SD of two biological replicates in 
quadruplicate. Statistical comparisons were made among all treatment groups and all 






FIG 20 Transport of arabinose in NTHi. The amount of arabinose left in conditioned 
media was measured after growing NTHi strains with and without an additional 
arabinose permease to (A) mid-log phase (approximate OD600 of 0.4) or (B) stationary 
phase (approximate OD600 of 1.3) to measure if arabinose transport was affected by 
metabolism and/or cell growth. The cells were pelleted and the medium passed through 
a 0.2 micron filter. The control was media treated identically to the conditioned media, 
but without NTHi. The conditioned media and the control were used to induce pGLO in 
E. coli LMG194 to compare the amount of arabinose remaining in the conditioned media 
to the control media. RFU per cell was calculated by dividing the total RFU by the 
number of cells (determined by the final OD595) for each strain. The fluorescence of the 
negative control (media alone) was subtracted from each value. Data are expressed as 
the mean + SD of two biological replicates in quadruplicate of each strain of conditioned 
media. Statistical comparisons were made between the results of the conditioned media 




The use of the PBAD promoter with the regulatory functions of AraC is an efficient 
and highly useful way to study gene expression in a number of different bacterial strains. 
Expanding its use to organisms that live in niche environments, such as NTHi, provides 
another tool to study genes that aid bacteria in causing infections in human hosts and 
evading the immune response. A good example is the type II TA systems, which have 
been shown to be crucial for the survival of NTHi during infection, both ex vivo in primary 
human tissues and in vivo in the chinchilla model of acute otitis media (36, 60).  
Other studies have successfully evaluated the use of the Ptrc (146) and the PxylA 
(149) in NTHi. The Ptrc promoter is induced by IPTG, a synthetic molecule similar to 
allolactose, but is not hydrolyzed by β-galactosidase. Because IPTG is not degraded, 
concentrations remain constant during experiments. Use of the PxylA promoter is a novel 
idea because, like the PBAD promoter, its tight regulation is particularly important for the 
study of essential or toxic genes. However, this promoter is induced by xylose, a five-
carbon sugar catabolized by many species, so it is important to verify catabolism genes 
in a species before utilizing this system. A number of studies have used the Pxyl from the 
particular species they are investigating and unlike promoters that are induced by IPTG 
and arabinose, there are no commercially-available plasmids that utilize Pxyl for gene 
expression.  
In this study, araC with PBAD::vapD was transformed into the chromosome of NTHi 
via homologous recombination at the site of a pseudogene. Two different arabinose 
permeases were also transformed into NTHi via homologous recombination at a 
bacteriophage terminase site to determine if an E. coli arabinose permease increased 
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arabinose transport across the membrane. Even when an arabinose permease was 
present, no significant amount of growth arrest upon induction of vapD in cis was 
observed (Fig. 18). It has been previously shown that the TA toxins VapC-1, VapD, and 
ToxA have ribonuclease activity (36, 46, 60, 85). It has also been shown that their 
corresponding TA operons contribute to survival of NTHi during infection (36, 60). 
However, it is important to note that the timeline of the assays utilized to measure effects 
on survival were over a period of 2-4 days. The first model, the EpiAirways (AIR 100 ABF; 
MatTek, Ashland, MA, USA), consists of primary human respiratory epithelial tissue at 
the air-liquid interface infected by NTHi over two (or more) days and is the closest in vitro 
model of the human upper airway that is currently available (108). In the second model, 
the chinchilla model of experimental otitis media, NTHi infection is quantified over four 
days and is extremely useful in the study of this and other auditory and respiratory tract 
infections due to the anatomical and physiological similarities between the chinchilla 
middle ear and that of humans (150). Through fluorescence measurements of pGLO in 
E. coli LMG194, the equal concentrations of arabinose in conditioned media compared to 
the arabinose-only control demonstrated that arabinose did not cross the NTHi membrane 
even with the addition of an E. coli arabinose permease (Fig. 20). It may be useful to 
explore araC with PBAD::vapD and permease induction with arabinose on a plasmid in 
trans in the background of NTHi. However, it would difficult to induce the antitoxin, toxin, 
and a permease in trans because all three plasmids would need to be compatible in the 
background of NTHi. This is a challenging task due to the diversity of the NTHi genome 
(151). H. influenzae strains are naturally competent and can transport several hundred 
kilobases of foreign DNA fragments at a time from the environment (152, 153). The 
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advantages of DNA uptake include using the nucleotides as a food source, repair of 
damaged DNA, and recombination into the chromosome to acquire new genes that may 
be beneficial to cellular survival. The latter has implications in plasmid maintenance 
because new DNA that has homologously recombined into the chromosome of H. 
influenzae could be antibiotic resistance genes, new virulence factors, or origins of 
replication that may affect plasmid replication. A large challenge faced while conducting 
experiments with NTHi has been differences in plasmid survivability between two NTHi 
strains, namely 86-028NP and R2866. In fact, it was not possible to construct the araC 
with PBAD::vapD recombinant at the targeted pseudogene site in 86-028NP. For reasons 
currently unknown, the 86-028NP strain generated only spontaneous mutants rather than 
recombinants (data not shown).   
H. influenzae survives as a commensal in a niche environment, the upper 
respiratory tract of the human host, a unique setting. It can also act as a pathogen in the 
middle ear, nasopharynx, and lung (154). Finally, it can invade the bloodstream and the 
cerebrospinal fluid (CSF) as well (155). These areas differ greatly in nutrient and oxygen 
availability (156). For example, mucous membranes, biofilms, and the middle ear have 
limited oxygen levels (157) compared to epithelial surfaces (158). Serum-resistant 
invasive strains can disrupt epithelial cells and penetrate into the bloodstream and 
ultimately cause infection of the CSF. However, the CSF is 99% water, which limits 
nutrients for H. influenzae (159), and has lower oxygen tension compared to that of the 
bloodstream. Therefore, it is necessary for NTHi to maintain genes that help it quickly 
adapt to these changes in its microenvironment (160). 
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A study of metabolic diversity in H. influenzae determined that all species 
maintained enzymes for the Embden-Meyerhof-Parnas (EMP) pathway (with the 
exception of glucokinase), and all the enzymes in the pentose phosphate pathway for 
glucose degradation (PPP) (161). As a follow-on, researchers investigated the metabolic 
and physiological properties of four strains: one respiratory tract isolate (Hi2019), two 
invasive strains (R2866 and C188), and the reference strain (Rd KW20) (156, 161, 162). 
However, even though the central carbon metabolic pathway is highly conserved among 
strains, pathway preference and carbon source utilization differed (156, 161). While 
interesting, this result is not unexpected; NTHi must quickly adapt to changes in the host 
in order to survive. Researchers have shown that NTHi has transport capabilities for 
glucose, xylose, ribose, galactose, fructose, glycerol, fucose, pyruvate, and sialic acid 
(152, 163, 164). Although NTHi has the ability to transport and catabolize a range of 
carbon sources, no reports mention arabinose availability in areas NTHi colonizes. NTHi 
does not maintain homologues to the arabinose transport and catabolism genes; 
however, it may be possible for another pathway to transport arabinose. While the 
bioassay to determine arabinose transport provided evidence that R2866 did not transport 
arabinose (Fig. 20), further investigation into arabinose transport and catabolism in other 
strains of NTHi might be valuable, as the use of the arabinose-inducible PBAD vectors 




MATERIALS AND METHODS 
Bacterial strains and culture conditions. The bacterial strains and plasmids 
used in these studies are listed in Table 6. E. coli strains were grown in LB broth or agar 
with or without 100 µg/mL ampicillin, 250 µg/ mL erythromycin, 20 µg/mL 
chloramphenicol, 100 µg/mL spectinomycin, or 10 µg/mL gentamicin, as required. E. coli 
strains were routinely cultured for 18 h at 37 °C.  NTHi strains were grown in brain heart 
infusion broth or agar supplemented with 10 μg/mL heme-histidine and 10 μg/mL β-NAD 
(sBHI), chocolate agar with 5 U/mL bacitracin, or defined media (147) with or without 
glucose supplemented with 10 mM sodium pyruvate. NTHi were routinely cultured for 18 
h at 37 °C with 5% CO2. To construct the ectopic strains, recombinants were selected on 
chocolate agar plates with 2 μg/mL chloramphenicol, 25 μg/mL spectinomycin, or 5 μg/mL 
erythromycin. Single colonies were passaged for 3 days on selection plates before being 
confirmed by DNA sequencing of PCR-amplified purified genomic DNA.  
Construction of an NTHi strain R2866 ΔvapXD mutant. The vapXD operon was 
previously deleted from NTHi strain 86-028NP (36). Due to the sequence homology 
between strains 86-028NP and R2866 flanking the vapXD operon (165), a PCR product 
from pDD788 (36) and the MIV transformation protocol (81) were used to create the 
R2866 ΔvapXD deletion mutant. Recombinants were selected on chocolate agar plates 
with chloramphenicol for three days. Genomic DNA preparations were used to 
characterize the deletion via PCR using primers that flanked the deletion.  
To compare the growth dynamics, the parent and mutant strains were re-
suspended from sBHI plates into fresh sBHI broth. The strains were grown to early log 
phase (OD600 of ~0.2 - 0.3) before being diluted into a 1:1 (vol:vol) ratio to a final volume 
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TABLE 5 Bacteria, plasmids and primers used in this study 
Strains Description Source 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
Laboratory 
collection 
LMG194 F- ΔlacX74 galE thi rpsL ΔphoA (PvuII) Δara714 
leu::Tn10 
Invitrogen 
DD12 MC4100 recA::RP4-2-Tc::Mu, kanamycin 
resistance 
(146) 
R2866 Blood isolate from an immunocompetent child with 
meningitis immunized with the Hib vaccine 
A.L. Smith 









R2866 ΔvapXD with araC with PBAD::vapD  and 





R2866 ΔvapXD with araC with PBAD::vapD  and 





R2866 ΔvapXD with araC with PBAD::vapD in cis 





 + (pDD1233) 
R2866 ΔvapXD with araC with PBAD::vapD  and 
ParaE::araE in cis and lacI






R2866 ΔvapXD with araC with PBAD::vapD  and 
ParaE::araFGH in cis and lacI
q with Ptrc::vapX in 
trans 
This work 
Plasmids Description Source 
pBAD33 Highly regulated expression vector, 
chloramphenicol resistant 
(77) 
pTrcHis2A Expression vector with C-terminal polyhistidine tag, 
ampicillin resistant 
Invitrogen 




TABLE 5 Continued   
Plasmids Description Source 
pSPEC1 Source of spectinomycin resistance cassette (166) 
pEJ18 Source of erythromycin resistance cassette (107) 
pGLO pBAD-GFPuv, ampicillin resistant Bio-Rad 
pDD514 RSF1010 ori broad host range vector, gentamicin 
resistant 
(146) 
pDD788 pBluescript SK(+) with the vapXD deletion (36) 
pDD1020 5’ end of R2866_RS09695 in pBluescript SK(+) This work 
pDD1021 3’ end R2866_RS09695 in pDD1020 This work 
pDD1022 R2866_RS09695 spectinomycin resistant -targeted 
delivery vector 
This work 
pDD1077 vapX in pTrcHis2A This work 
pDD1218 vapD in pBAD33 This work 
pDD1227 pDD1022 with araC with PBAD::vapD This work 
pDD1228 5’ end of R2866_RS04985 in pBluescript SK(+) This work 
pDD1229 3’ end R2866_RS04985 in pDD1229 This work 
pDD1230 NTHI_RS04985 erythromycin resistant - targeted 
delivery vector 
This work 
pDD1233 lacIq with Ptrc::vapX in pDD514 This work 
pDD1235 pDD1230 with araE This work 
pDD1236 pDD1230 with araFGH This work 
Primers Description Source 
PvapDXba+SDFor AAAATCTAGAATAAGGAAAATTATGTACG Eurofins 
pBAD33VapDHindRev TAGGAAGCTTTTAATTTCGTATAAAATCAG Eurofins 
VapXSKSacFor AAAAGAGCTCTATGGAACTAAGACAAC Eurofins 
86VapLexRev (KpnI) ATAAGGTACCTTATTCAGCTTCGG Eurofins 
Xlacl for (XbaI) GTCATCTAGAAAACGCGCGAGGCAGC IDT 
Xhis rev (XbaI) TATTTGTCTAGAGGCAGTTCCCTACTCTCG IDT 
1356-1SacFor AAAAGAGCTCAACTTAAACAAGCTC Eurofins 
1356-1SpeRev AATTACTAGTAGCCTCTTCAATAC Eurofins 
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TABLE 5 Continued   
Primers Description Source 
1356-2XhoFor TTTCCTCGAGTTTAGCGGTGAATGG Eurofins 
1356-2KpnRev AAAAGGTACCACACCCAACCACTTC Eurofins 
SpecPstFor ACAACTGCAGAGATCTATCGATTTTCG Eurofins  
SpecPstRev AAGCCTGCAGAGATCTGTACATCG Eurofins 
pBAD33BgIIIRev TTATAGATCTTATTGTCTCATGAG Eurofins  
pBAD33BgIIIFor TATCAGATCTGCATAATGTGC Eurofins  
RS04985-1SacFor ATTTGAGCTCAAATTCCGACCGCTC Eurofins 
RS04985-1XbaRev AGTATCTAGACCAAGTTTGAGATGC Eurofins  
RS04985-2XhoFor AAGGCTCGAGTTGATGTGGCAGATG Eurofins  
RS04985-2KpnRev AAAAGGTACCGGCGTAGCACATAAC Eurofins  
PermCSpeFor AAATACTAGTAACACACACGCCATTCC Eurofins  
ErmCSpeRev GTTAACTAGTGCAGTTATGCATCC Eurofins  
ParaESpeFor GATGACTAGTATAGTGTTCCTTGCC Eurofins  
AraESpeStopRev TTAAACTAGTTCAGACGCCGATATTT Eurofins  
ParaFGHSpeFor AGGCACTAGTTATGGATTAATCTGC Eurofins  




of 150 microliters of media in a 96-well Falcon polystyrene microplate (Corning, Corning, 
NY). The plate was covered with a gas permeable membrane, loaded into a Multiskan 
FC incubating plate reader (Thermo Fisher Scientific, Waltham, MA USA), and incubated 
at 35°C with a shaking protocol of five seconds on, five seconds off with measurements 
taken every 10 mins at OD595 for 7 h. Each growth assay included three biological 
replicates with three technical replicates.  
Construction of artificially-inducible NTHi genes in E. coli. To transform this 
system into NTHi, the toxin, vapD, was cloned into plasmid pBAD33 so that it was under 
control of an arabinose-inducible promoter. NTHi strain 86-028NP genomic DNA was 
used to amplify vapD with PvapDXba+SDFor and pBAD33VapDHindRev primers. After 
digestion with XbaI and HindIII, the PCR fragment was ligated to pBAD33, resulting in 
pDD1218 (vapD under the control of the PBAD promoter). VapXSKSacFor and 
86VapLexRev primers were used to amplify vapX from 86-028NP genomic DNA. The 
PCR fragment was digested with SacI and KpnI and ligated to pTrcHis2A, resulting in 
pDD1077 (vapX under the control of the Ptrc promoter). XlacIFor and XhisRev primers 
were used to amplify pDD1077. This PCR product was digested with XbaI and ligated to 
the broad-host range conjugal vector, pDD514 (146), resulting in pDD1233.    
Construction of the in cis delivery systems and reconstituted NTHi strains. 
Based on previously published ectopic delivery vectors in NTHi (106, 143), two locations 
in the genome of R2866 were targeted for gene delivery. The metH pseudogene 
(R2866_RS09695) and the large subunit of the PBSX phage terminase gene 
(R2866_RS04985) were chosen as sites for gene delivery in cis. The large subunit of the 
PBSX phage terminase gene was chosen because R2866 only maintains a portion of the 
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PBSX bacteriophage genome.  After scrutiny of the R2866 genome, it was determined 
that this gene would provide enough flanking regions to enable the homologous 
recombination of a large PCR product into the genome without impeding vital genes 
necessary for bacterial metabolism and replication. 
The R2866_RS09695 targeted delivery vector was constructed by amplifying 899 
bp of the 5’ end of R2866_RS09695 from R2866 genomic DNA with 1356-1SacFor and 
1356-1SpeRev primers and ligating the product into pBluescript SK(+) digested with SacI 
and XbaI (produces a compatible overhang which can be ligated to SpeI), resulting in 
pDD1020. The second homologous region of 953 bp of the 3’ end of R2866_RS09695 
was amplified from R2866 genomic DNA with 1356-2XhoFor and 1356-2KpnRev primers 
and ligated into pDD1020 digested with XhoI and KpnI, resulting in pDD1021. The last 
step was amplifying a spectinomycin resistance cassette from pSPEC1 (166) with 
SpecPstFor and SpecPstRev primers and ligating to pDD1021 digested with PstI, 
resulting in the delivery vector, pDD1022 (Fig. 16A). The primers pBAD33BgIIIFor and 
pBAD33BgIIIRev were used to amplify pDD1218. The PCR product was digested with 
BglII and ligated into pDD1022 digested with BamHI (produces a compatible overhang 
which can be ligated to BgIII), resulting in pDD1227 (Fig. 16B). This arabinose-inducible 
targeted delivery vector resulted in the fusion of araC to the PBAD promoter controlling 
vapD. 
R2866 ΔvapXD was made chemically competent (81) and the R2866 ΔvapXD 
RS09695::araC with PBAD::vapD mutant was constructed by homologous recombination 
of the PCR product using pDD1227 template. After selection on chocolate agar with 25 
µg/mL spectinomycin, a single colony of each transformant was passaged three times on 
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antibiotic-containing plates. DNA sequencing of PCR-amplified genomic DNA 
preparations confirmed the correct strain. 
The R2866_RS04985 delivery vector was constructed by amplifying 697 bp of the 
5’ end of R2866_RS04985 from R2866 genomic with RS04985-1SacFor and RS04985-
1XbaRev primers and ligating the product into pBluescript SK(+) digested with SacI and 
XbaI, resulting in pDD1228. The second homologous region of 592 bp of the 3’ end of 
R2866_RS04985 was amplified from R2866 genomic DNA with RS04985-2XhoFor and 
RS04985-2KpnRev primers and ligated into pDD1228 digested with XhoI and KpnI, 
resulting in pDD1229. The last step was amplifying an erythromycin resistance cassette 
from pEJ18 (107) with PermCSpeFor and ErmCSpeRev primers and ligating into 
pDD1229 digested with SpeI, resulting in the second delivery vector, pDD1230 (Fig. 17A).  
Two different arabinose permeases were amplified from E. coli strain DH5α 
genomic DNA to individually clone into pDD1230. The first permease, the low-affinity 
arabinose transporter, araE, was amplified with ParaESpeFor and AraESpeStopRev 
primers. The second permease, the high-affinity arabinose transporter, araFGH, was 
amplified with ParaFGHSpeFor and AraFGHSpeRev primers. Both products were 
digested with SpeI and ligated into pDD1230, resulting in pDD1235 and pDD1236, 
respectfully (Fig. 17B and C).  
R2866 ΔvapXD R2866_RS09695::araC with PBAD::vapD was made chemically 
competent (81) to independently transform pDD1235 and pDD1236 into the chromosome, 
resulting in R2866 ΔvapXD R2866_RS09695::araC with PBAD::vapD 
RS04985::ParaE::araE and R2866 ΔvapXD R2866_RS09695::araC with PBAD::vapD 
RS04985::ParaFGH::araFGH. After selection on chocolate agar with 5 µg/mL erythromycin, 
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a single colony of each transformant was passaged three times on antibiotic-containing 
plates. PCR-characterized genomic DNA preparations confirmed each correct strain. 
Construction of the in trans delivery systems into reconstituted NTHi strains. 
The antitoxin, VapX, was cloned into pDD1233 as previously mentioned. To induce VapD 
and VapX independently in the same strain, it was necessary to utilize two different 
promoters with different inducers. Due to the small, finely tuned genome size of many 
NTHi strains, it is particularly difficult to find unnecessary areas of the genome to utilize 
for targeted delivery systems. For this reason, the antitoxin in pDD1233 was conjugated 
into the newly constructed strains R2866 ΔvapXD R2866_RS09695::araC with 
PBAD::vapD,  R2866 ΔvapXD R2866_RS09695::araC with PBAD::vapD 
RS04985::ParaE::araE, and R2866 ΔvapXD R2866_RS09695::araC with PBAD::vapD 
RS04985::ParaFGH::araFGH (146). After selection on chocolate agar with 5 µg/mL 
gentamicin, transconjugates were passaged three times on antibiotic-containing plates. 
PCR-characterized plasmid preparations confirmed that pDD1233 was successfully 
transferred to each strain. 
Modulation of expression of GFP in glucose-free defined media. The plasmid 
pGLO in E. coli LMG194 was used to measure the expression of GFP. The LMG194 
strain with pGLO was re-suspended from glucose-free defined media with 10 mM sodium 
pyruvate agar and 100 µg/mL ampicillin into identical broth media without agar to an 
approximate OD600 of 0.16. The re-suspended culture was diluted into a 1:1 (vol:vol) ratio 
to a final volume of 150 microliters of medium in a 96-well Falcon polystyrene microplate 
(Corning, Corning, NY) containing identical media with 100 µg/mL ampicillin and 26.4 mM 
(0.4% wt/vol) arabinose in four 10-fold dilutions down to 0.0264 mM (0.0004% wt/vol) or 
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media without arabinose. The final induction concentrations were 13.2 (0.2% wt/vol), 1.32 
mM (0.02% wt/vol), 0.132 mM (0.002% wt/vol), and 0.0132 mM (0.0002% wt/vol) 
arabinose. The plate was covered with a gas permeable membrane, loaded into a 
Multiskan FC incubating plate reader (Thermo Fisher Scientific, Waltham, MA USA), and 
incubated at 35 °C with a shaking protocol of five seconds on, five seconds off for 12 h. 
The final OD595 was recorded and florescence intensity was measured (405 nm excitation, 
520 nm emission) on a FLUOstar OPTIMA Microplate Reader (BMG LABTECH, 
Ortenberg, Germany).  For E. coli, each 0.1 OD unit of absorbance equals approximately 
1.0 x 108 cells/mL (167). Using the final OD595, the number of cells per treatment group 
were calculated to determine the RFU/cell. Each assay included two biological and four 
technical replicates. 
Measuring the transport of arabinose in NTHi. The strains were re-suspended 
from glucose-free defined media with 10 mM sodium pyruvate agar plates into identical 
fresh media without agar at an initial OD600 of 0.1. They were immediately induced with 
2.65 mM (0.04% wt/vol) arabinose and grown to mid-log phase (approximate OD600 of 
0.4) or stationary phase (approximate OD600 of 1.3). When the final OD600 was reached, 
aliquots were centrifuged at 13,000 x g for 10 min to pellet cells and cell debris. The 
supernatant was filter-sterilized through a 0.2 micron polyethersulfone membrane. The 
control was treated identically to the conditioned media except it was not inoculated with 
NTHi. The sterilized supernatants (conditioned media and NTHi-free media control) were 
used in the pGLO in LMG194 fluorescence assays to determine if there was a difference 
in arabinose concentrations remaining in the conditioned media versus the control.  
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pGLO in LMG194 was re-suspended from glucose-free defined media with 10 mM 
sodium pyruvate agar and 100 µg/mL ampicillin into identical media without agar to 
approximately OD600 0.16. The re-suspended culture was diluted into a 1:1 (vol:vol) ratio 
to a final volume of 150 microliters of media in a 96-well microplate with the conditioned 
media and control. The same protocol described in the pGLO fluorescence experiment 
was used to measure GFP fluorescence induced by the conditioned media and control. 
Each assay included three biological and four technical replicates.    
Statistical analyses. Differences among multiple-group treatments were 
determined by the one-way or the repeated-measures ANOVA as appropriate using 
GraphPad Prism 8.1.2 (GraphPad Software, La Jolla, CA USA). A P value of <0.05 was 
considered statistically significant.  
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ANALYSIS OF THE GENOME ORGANIZATION OF FOUR TA LOCI IN 12 CLINICAL 
ISOLATES OF NONTYPEABLE HAEMOPHILUS INFLUENZAE 
INTRODUCTION 
In 1995, H. influenzae was the first free-living organism to have its genome 
sequenced (168). This sparked the “genome era” and since then, 204,683 partial and 
whole bacterial sequences, 735 being Haemophilus influenzae strains, have been 
deposited into Genbank (169). As the community shifts from Sanger sequencing to next-
generation sequencing (NGS), it has become much more feasible for clinicians and 
researchers to quickly and accurately sequence the genomes of bacterial isolates in-
house and analyze the data (170). These higher-throughput methods are useful for 
tracking epidemiological data and targeting current or potential outbreaks. NGS can also 
be a beneficial way to customize treatment plans by sequencing the causative agent(s) 
of major bacterial infections and tailoring antimicrobial therapy based on the resistance 
genes present in the isolates involved in the infection. Targeted therapy is predicted to 
become an increasing focus because unintended consequences of antibiotic use can 
alter the microbiome, activate toxin-antitoxin systems, establish of environmental 
reservoirs, and increase the speed in which bacteria develop resistance to current drugs 
(145). A list of FDA-approved antibiotics and their approval years was recently reported 
(145). There was an increase in approval of new antibiotics from the late-1930’s until the 
mid-1980’s (Fig. 21). After that time, there was a steady decline in FDA-approved 
antibiotics. The increase in antibiotic resistance and decreased support for antibiotic drug 
discovery has led researchers to investigate other antimicrobial therapy approaches. A 







FIG 21 FDA approved antibacterial drugs for use in humans from 1936-2016. 
Antibacterial drugs approved by the US Food and Drug Administration (FDA) for use in 
humans. This plot shows the number of drugs approved within five-year periods from 
1939 until 2017 (all drugs are listed in Table 1 of reference 145). The 157 drugs are 
grouped according to 20 classifications as shown by the legend. The greatest number of 
drugs were approved between 1981 and 1985. This image is reproduced from reference 
145 reviewing FDA approved small molecule drugs, unintended consequences of 




Nontypeable Haemophilus influenzae (NTHi) is a model organism to study one of 
the sub-families of the type II TA modules, the vap genes, because it maintains four vap 
operons in its very small (~2 Mbp) genome (36). This organism is human-adapted, 
meaning that there are no animal or environmental reservoirs for NTHi; it lives exclusively 
in humans. This trait has facilitated its evolution as a human commensal, living in the 
human upper airway without causing symptoms. Due to this lifestyle, NTHi strains have 
lost the genes necessary to synthesize many cofactors such as nicotinamide adenine 
dinucleotide (NAD) as well as heme, and scavenges these essential molecules from the 
host.  Interestingly, however, this bacterium can also cause infections such as otitis 
media, bronchitis, and can invade the cerebrospinal fluid (CSF). These infection sites all 
vary in the amount of heme and NAD available.    
NTHi is one of the leading causes of recurrent otitis media (17), infections that 
result in >$4 billion in health-care costs annually (18-20). This study sought to investigate 
the prevalence of type II TA modules in many NTHi strains as a potential therapeutic 
target. Type II TA loci contribute significantly to the survival and virulence of NTHi during 
infections and these loci increase bacterial persistence and dormancy following stress 
(36, 60).  Due to the increase of antibiotic-resistant NTHi strains and the lack of a suitable 
vaccine to prevent these infections, the prevalence and genomic organization of four 
important, highly conserved type II TA loci in NTHi, vapBC-1, vapBC-2, vapXD, and 
toxAvapA, was investigated in 12 recently-sequenced clinical isolates. It was previously 
determined that a single mutation in the conserved region of the PIN domain in VapC-1 
causes a significant decrease in survivability of NTHi strain 86-028NP (Fig.13) (143). The 
vap genes are part of pathogenicity islands (PAI), that are transferred between organisms 
79 
 
via horizontal gene transfer (HGT) to help them adapt to new ecological niches (171, 
172). Continuing to study TA systems in H. influenzae is a novel way to exploit a potential 
antibacterial target. Due to the conservation of type II TA operons, this approach could 





Sequences. Identification and genomic analysis of H. influenzae has evolved from 
16S rRNA genes sequencing, DNA-DNA hybridization and multilocus sequence typing 
(MLST), to whole-genome sequencing (WGS) facilitated by next-generation sequencing 
(NGS) (4, 22, 173-175). In an effort to contribute to genomic studies that have helped 
identify genes associated with virulence, growth, persistence, and nutrient acquisition, 12 
clinical isolates of NTHi were sequenced (Table 6) on the IlluminaTM MiSeq platform. 
Sequence assembly was completed in the Velvet de novo Assembly BaseSpace Labs 
application (Illumina) against NTHi strain 86-028NP (NC_007146.2). Strain 86-028NP 
(176) was chosen as the reference strain instead of Rd KW20 (168) because Rd is a 
laboratory strain with reduced virulence compared to the clinical isolate 86-028NP, and 
because 86-028NP has been validated in the chinchilla model of otitis media (177) and 
the primary human respiratory tissue model (EpiAirway, AIR 100 ABF; MatTek, Ashland, 
MA) (178).  
Protein conservation and alignment. The genomes of the 12 recently-
sequenced clinical isolates were used to investigate the conservation of type II TA 
modules in NTHi. Utilizing the PATRIC Basic Local Alignment Search Tool (BLAST) 
service (179), the 12 genomes were queried against the amino acid sequence of the 
antitoxin and toxin protein products of the following operons from the reference strain 86-
028NP: vapBC-1, vapBC-2, vapXD, and toxAvapA (Table 8). The assumption was made 
that if the strain had both proteins in an operon, then it maintained the corresponding TA 
locus. After determining which isolates maintained the genes that produced the protein 
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products listed in Table 8, multiple sequence alignments were performed using Clustal 




TABLE 6 Sequencing, assembly, and annotation metrics of NTHi strains sequenced on 






















C294 151 1,053,389 83 1,807,236 79 92251 38.1 1842 
C37 151 932,918 74 1,950,111 150 36486 38.1 2038 
C447 151 965,862 76 1,916,993 92 59454 38.0 1951 
C464 151 1,030,333 81 1,861,829 142 60580 38.0 1916 
C470 151 940,232 74 1,894,592 97 57870 38.0 1922 
R3001 151 1,025,145 81 1,826,634 89 72043 37.9 1830 
R3168 151 590,531  47 1,958,029 144 91827 38.2 2002 
R3171 151 552,672 44 1,780,770 83 101141 37.9 1761 
R3172 151 501,645 40 1,810,932 72 79083 38.0 1791 
R3175 151 536,811 42 1,788,908 102 74349 37.9 1781 
R3176 151 532,429 42 1,908,985 90 114115 38.0 1955 
R3177 151 456,581 36 1,921,437 103 67411 38.2 1988 
aN = aligned reads for Read 1 and Read 2 combined  
bCoverage = (L X N)/Reference genome bp (1,914,490 bp).  
cCoding sequences   
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TABLE 7 Percent Identity Protein BLAST results against NTHi strain 86-028NP 
 Protein 
Strain VapB-1 VapC-1 VapB-2 VapC-2 VapX VapD ToxA VapA 
C294 Xa Xa 100 100 97 93 100 100 
C37 99 97 100 100 Xa Xa 100 100 
C447 Xa Xa 100 99 97 99 100 100 
C464 100 100 100 100 100 100 99 100 
C470 100 100 100 99 98 47b 100 100 
R3001 99 99 100 100 100 100 100 100 
R3168 Xa Xa 100 99 98 97 100 99 
R3171 99 99 100 100 98 49b 100 100 
R3172 99 99 100 99 98 47b  100 100 
R3175 99 99 100 100 98 49b 99 88 
R3176 100 100 100 99 100 100 100 100 
R3177 99 99 Xa Xa 98 99 98 94 
aStrain is missing the TA locus 





vapBC-1. Nine out of the 12 strains maintained the vapBC-1 locus. Three of the 
strains (C464, C470, and R3176) shared 100 percent protein identity to the VapB-1 
antitoxin (WP_005649046.1) and the VapC-1 toxin (WP_005649049.1) from the 
reference strain 86-028NP. The remaining six strains (C37, R3001, R3171, R3172, 
R3175, and R3177) were 99 percent identical to the 86-028NP VapB-1 antitoxin. They 
shared the same, semi-conservative amino acid change at position 3 (threonine to 
alanine). Five strains (R3001, R3171, R3172, R3175, and R3177) had a 99 percent 
identity score, and C37 had a 97 percent identity to the 86-028NP VapC-1 toxin. All six 
strains shared the same conserved mutation at position 21 (isoleucine to valine) and at 
position 36 (methionine to isoleucine). In strain C37, an additional amino acid mutation in 
VapC-1 is a conserved mutation at position 93 (arginine to glutamine).  
vapBC-2. Eleven of the 12 strains maintain the vapBC-2 locus; strain R3177 is the 
only one that does not. The 11 strains shared 100 percent identity to the 86-028NP VapB-
2 antitoxin (WP_005648011.1). Strains C447, C470, R3168, R3172, and R3176 are 99 
percent identical to the 86-028NP VapC-2 toxin (WP_005651560.1) and share the same 
non-conservative mutation at position 59 (valine to glycine), with the exception of strain 
R3168 which has a semi-conserved mutation at position 17 (arginine to histidine).  
vapXD. Eleven of the 12 strains maintain the vapXD locus; strain C37 is the only 
one that does not. Three strains, C464, R3001, and R3176 are 100 percent identical to 
the 86-028NP VapX antitoxin (WP_011272059.1) and the VapD toxin 
(WP_011272058.1). Strains C470, R3168, R3171, R3172, R3175, and R3177 are 98 
percent identical to 86-028NP VapX and strains C294 and C447 are 97 percent 
identical. All eight strains have a conserved mutation at position 55 (tyrosine to 
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histidine) in VapX and the two strains that are 97 percent identical (C294 and C447) 
have a semi-conserved mutation at position 36 (valine to alanine). Surprisingly, the 
VapD toxin sequence had the most variation. Strains C447 and R3177 are 99 percent 
identical and have a semi-conserved mutation at position 23 (glutamic acid to 
glutamine). Strain R3168 is 97 percent identical and has the same semi-conserved 
mutation at position 23 (glutamic acid to glutamine) as well as a non-conserved 
mutation at position 30 (alanine to glutamic acid), and a semi-conserved mutation at 
position 31 (valine to threonine). Strain C294 is 93 percent identical and has the semi-
conserved mutation at position 23 (glutamic acid to glutamine), two deletions at 
positions 40 and 41 (threonine and glutamine), a non-conserved mutation at position 48 
(methionine to threonine), a conserved mutation at position 61 (alanine to serine), and a 
conserved mutation at position 92 (asparagine to serine). Interestingly, four out of the 
12 strains (C470, R3171, R3172, and R3175) have a 47 amino acid deletion from 
position 30 to 77 that was previously identified in five other strains (85). In addition to 
the truncation, strains C470 and R3172 also have the semi-conserved mutation at 
position 23 (glutamic acid to glutamine) mutation. Strains R3171 and R3175 have a 
non-conserved mutation at position 29 (glycine to arginine). 
toxAvapA. This type II TA locus is interesting because unlike the previously 
described TAs, toxAvapA (a homologue of the host inhibition of growth locus higBA (183)) 
is arranged with the toxin directly upstream of the antitoxin. This gene pair exhibits two 
promoters, one for the toxin and a second for the antitoxin, a characteristic that likely 
contributes to the stability of the antitoxin. All 12 strains maintain the toxAvapA locus. 
Eight strains (C294, C37, C447, C470, R3001, R3171, R3172, and R3176) are 100 
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percent identical to both the 86-028NP ToxA toxin (WP_005650215.1) and the 86-028NP 
VapA antitoxin (WP_005650217.1). Strain C464 is 99 percent identical to ToxA with a 
non-conserved mutation at position 59 (leucine to serine). Strain R3175 is also 99 percent 
identical with a non-conserved mutation at position 79 (arginine to cysteine). Strain R3177 
is 98 percent identical with a semi-conserved mutation at position 23 (threonine to 
alanine) and a non-conserved mutation at position 32 (tyrosine to serine). Strain 3168 is 
99 percent identical to VapA with a semi-conserved mutation at position 39 (alanine to 
valine). Strain R3177 is 94 percent identical to VapA and has 6 mutations: conserved at 
position 26 (serine to asparagine); semi-conserved at position 60 (valine to alanine); 
conserved at position 79 (aspartic acid to asparagine); non-conserved at position 95 
(proline to serine); non-conserved at position 101 (aspartic acid to glycine); and semi-
conserved at position 104 (threonine to alanine). Interestingly, R3177 has a 13 amino 
acid truncation at N-terminus of VapA, however, ToxA is maintained at its full length. A 
BLAST search based upon the protein sequence does not reveal any more strains with 







FIG 22 VapBC-1, VapBC-2, VapXD, and ToxAVapA CLUSTAL O (1.2.4) multiple 
sequence alignments (MSA). The protein sequences belonging to four virulence 
associated protein (vap) operons from NTHi strain 86-028NP were used to BLAST 12 
clinical isolates recently sequenced at Old Dominion University. Strains are listed in the 
following order for all MSAs:  86-028NP, C294, C37, C447, C464, C470, R3001, R3168, 
R3171, R3172, R3175, R3176, R3177. Strains not included in the alignment are marked 
with a caret in the figure legend. MSAs of the following proteins VapB-1 C294^, C447^, 
and R3168^ (A); VapC-1 C294^, C447^, and R3168^ (B); VapB-2 R3177^ (C); VapC-2 
R3177^ (D); VapX C37^ (E); VapD C37^ (F); ToxA (G); VapA (H). An asterisk indicates 
positions which have a single, fully conserved residue; a colon indicates conservation 
between groups of strongly similar properties; a period indicates conservation between 
groups of weakly similar properties according to the Gonnet PAM 250 matrix. The colors 
represent physiological properties of the amino acids: red (small, hydrophobic), blue 










































TA loci organization. By using the protein BLAST service (179), it was 
determined that seven of the strains (C454, C470, R3001, R3171, R3172, R3175, and 
R3176) had all four vap operons and the remaining five strains (C294, C37, C447, R3168, 
and R3177) were missing one operon each. Strains C294, C447, and R3168 were 
missing vapBC-1; strain R3177 was missing vapBC-2; and strain 37 was missing vapXD. 
The next step was to determine if the four vap loci were located on the genome in the 
same region as the reference strain 86-028NP. Location was considered an important 
factor because even though NTHi is genetically diverse, the TA loci are important for 
bacterial survival and therefore conservation and maintenance are necessary. If the TA 
loci were not in the same regions as the reference genome, it could indicate that the 
genes were acquired at different times and by different means, such as by horizontal gene 
transfer from other microorganisms or from a bacteriophage. A region of one kilobase 
directly upstream and downstream of each vap operon was used in the PATRIC BLAST 
service (179) to query the 12 recently-sequenced strains to determine if the organization 
of the identified operons was the same as the reference sequence (Table 8). It was 
determined that all four vap operons shared the same flanking regions as in the reference 
strain 86-028NP.  
Phylogenetic tree. Phylogenetic trees are important because they can illustrate 
evolutionary relationships among biological species. These ancestral relationships can 
offer some insight into potential treatments against infections caused by NTHi. For 
example, two recently diverged strains would have more nucleotides in common than two 
strains from different clades. While a phylogenetic tree will not differentiate what those 
similarities and differences are, exploring the genomes and past clinical records of the 
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TABLE 8 Operon location BLAST results against a two kilobase region around each 
vap operon from 86-028NP 
 Gene 
Strain vapBC-1 vapBC-2 vapXD toxAvapA 
C294 N/Aa Conserved Conserved Conserved 
C37 Conserved Conserved Conserved Conserved 
C447 N/Aa Conserved Conserved Conserved 
C464 Conserved Conserved Conserved Conserved 
C470 Conserved Conserved Conserved Conserved 
R3001 Conserved Conserved Conserved Conserved 
R3168 N/Aa Conserved Conserved Conserved 
R3171 Conserved Conserved N/Aa Conserved 
R3172 Conserved Conserved Conserved Conserved 
R3175 Conserved Conserved Conserved Conserved 
R3176 Conserved Conserved Conserved Conserved 
R3177 Conserved N/Aa Conserved Conserved 





strains may provide insight on virulence factors.  
The Codon Tree application in PATRIC (184) was used to build two phylogenetic 
trees, then upload them into the Interactive Tree of Life (ITOL) (185). The first tree was 
built with the 12 clinical isolates recently sequenced at ODU (Fig. 23). This tree was 
generated using 1000 protein sequences (a total of 399,105 aligned amino acids) and 
953 gene sequences (1,130,649 aligned nucleotides). The second tree included 27 
additional H. influenzae sequences collected from GenBank (169) (Table 9). This tree 
was generated using 977 protein sequences (a total of 309,629 aligned amino acids) and 
900 gene sequences (845,211 aligned nucleotides). Two trees were built using PATRIC 
software to observe how the clinical isolates are distributed among a sampling of the H. 
influenzae population (Fig. 24). Many of the 27 typeable and nontypeable strains 
chosen have been previously studied, and a mixture of invasive and non-invasive strains 
was included to investigate the relationship of the recently-sequenced strains to the NTHi 









FIG 23 Phylogenetic tree of 12 NTHi clinical isolates recently sequenced at Old 
Dominion University. The Codon Tree application in PATRIC was used to build a 
phylogenetic tree with 12 clinical isolates of NTHi using 1000 protein sequences (a total 
of 399,105 aligned amino acids) and 953 gene sequences (1,130,649 aligned 
nucleotides). The tree was viewed in iTOL. Only bootstrap values of less than 100 are 





TABLE 9 Strains used to generate phylogenetic trees 
Strain Type Description Source 
C294a NT Pericardium A.L. Smith 
C37a NT Sputum from a patient with 
chronic lung disease 
A.L. Smith 
C447a NT Ear A.L. Smith 
C464a NT Ear A.L. Smith 
C470a NT Ear A.L. Smith 
R3001a NT Bronchial lavage of a pediatric 
cystic fibrosis patient 
A.L. Smith 
R3168a NT Blood from Hib vaccinated 
patient 
A.L. Smith 
R3171a NT Blood from Hib vaccinated 
patient 
A.L. Smith 
R3172a NT Blood from Hib vaccinated 
patient 
A.L. Smith 
R3175a NT Blood from Hib vaccinated 
patient 
A.L. Smith 
R3176a NT Blood from Hib vaccinated 
patient 
A.L. Smith 
R3177a NT Blood from Hib vaccinated 
patient 
A.L. Smith 
2019 NT Sputum (186) 
60294N1 NT Nasopharyngeal isolate (187) 
723 NT OME isolate (173) 
86-028NP NT Nasopharyngeal isolate from a 
pediatric OM patient  
R.S. 
Munson, Jr. 
CGSHiCZ412602 NT OME isolate  
NCTC 8143 NT Type strain (ATCC 33391)  
PitAA NT OME isolate  (188) 
PitEE NT OME isolate  (188) 
PitGG NT OME isolate  (188) 
PitHH NT OME isolate  (188) 
PitII NT OME isolate  (188) 
R2846 NT AOM patient A.L. Smith 
R2866 NT Blood isolate of a child with 
meningitis immunized the with 
Hib vaccine 
A.L. Smith 
R3021 NT 22.4-21 (21) 
NML-Hia-1 a Blood isolate (189) 
Hi609 a Blood isolate (190) 
ATCC 10211 b AMC 36-A-[572]  
10810 b Isolated from a meningitis patient (191) 
NCTC 11394 b Unknown  
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TABLE 9 Continued   
Strain Type Description Source 
NCTC 13377 b Unknown  
M12125 c Unknown  
Rd KW20 NT Type d derivative  (168) 
Hi467 e CSF of meningitis patient (192) 
KR494 f Necrotizing myositis (193) 
WAPHL1 f Blood isolate (194) 
M21384 hybrid Unknown (195) 
NCTC 11426 hybrid Unknown (195) 




FIG 24 Phylogenetic tree of 39 strains of H. influenzae. Twelve NTHi clinical isolates 
recently sequenced at ODU and 27 typeable and nontypeable invasive and noninvasive 
sequenced strains collected from GenBank were used to generate a phylogenetic tree 
with the Codon Tree application in PATRIC using 977 protein sequences (a total of 
309,629 aligned amino acids) and 900 gene sequences (845,211 aligned nucleotides). 
The tree was viewed in iTOL. Only bootstrap values of less than 100 are reported. 
Strains highlighted in purple are the 12 isolates recently sequenced at ODU. Strains 
highlighted in green are encapsulated strains from the 27 sequences collected from 
GenBank. The strains not highlighted are unencapsulated strains from the 27 








H. influenzae is a host-adapted human pathogen, and genomic studies have 
determined that approximately two-thirds of its proteins have homologues in E. coli. 
Most of the genome reduction is due to the loss of paralogues (196). This evolution is 
advantageous to an obligate parasite of the human upper respiratory tract because it is 
metabolically expensive to maintain duplicate genes or genes that transport and 
catabolize products the organism does not need for survival and may never encounter 
in its native microenvironment. Encapsulated strains, especially H. influenzae serotype 
type b (Hib), are significantly more clonal than NTHi (173, 197-199). This could be the 
result of the protective nature of the capsule in typeable strains, which does not facilitate 
the acquisition of new DNA via horizontal gene transfer in the DNA-rich environment of 
their human hosts. However, NTHi strains are naturally competent, and their high rate of 
DNA uptake and homologous recombination significantly influences the genetic diversity 
of the species (175, 200). Twelve clinical isolates were sequenced to learn more about 
the genetic diversity and to investigate the conservation of four TA loci: vapBC-1, 
vapBC-1, vapXD, and toxAvapA.  
Trillions of microorganisms cohabitate with their human hosts all over the body in 
various anatomical sites (gut, mouth, skin, vagina, upper respiratory tract) (201). 
Microbiome and normal flora are terms used to describe this harmonious relationship, 
and this niche occupation helps prevent the overgrowth of pathogens. However, stress 
imposed on the body, such as that caused by an infection, antibiotic use or a change in 
diet, can disrupt the normal flora (202). This disruption can result in both commensal 
and opportunistic organisms becoming pathogenic by either increasing in numbers or 
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migrating into normally sterile sites and causing infections (203). NTHi is an 
opportunistic organism, and a study by Kaur et al. determined no major phylogenetic 
differences between asymptomatic colonizing strains and strains that caused acute 
otitis media (AOM) (204). Studies have linked TAs to the survival of environmental and 
pathogenic bacterial species, which is why it is so important to continue to investigate 
the conservation of these operons and exploit them as potential antimicrobial drug 
targets (205, 206).  
This study sequenced 12 invasive and noninvasive clinical isolates of NTHi from 
a range of infection sites in the body including: two sputum, three ear, and seven blood 
isolates. Using those sequences and various applications in PATRIC, it was determined 
that all 12 isolates had at least three of the four vap operons of interest, and seven of 
these strains (58%) maintained all four TAs. In the five strains that maintained three of 
the vap operons, vapBC-1 was not maintained in three, vapBC-2 was not maintained in 
one, and vapXD was not maintained in one. The percent identity of the antitoxin and 
toxin proteins compared to the sequences of strain 86-028NP was often 98-100 
percent. Five strains maintained three of the four TAs of interest. Three of these strains 
are considered invasive because they infected normally sterile sites (C294, R3168, and 
R3177), and two of these strains were considered noninvasive commensals (C37 and 
C447). Interestingly, none of the mutations in VapC-1 were in the PilT N-terminal (PIN) 
domain (62, 65). The largest difference in the amino acid sequence was a 47 amino 
acid deletion in VapD in four of the strains. This unique in-frame deletion was 
discovered in ten other clinical strains during a study that identified and characterized 
vapXD in 59 commensal and disease-causing isolates NTHi from the nasopharynx, 
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sputum/tracheal aspirate/ear, and blood/CSF (85). Daines et al. (2004) determined that 
this deletion occurred in 7% of the nasopharynx, 50% of the sputum/tracheal 
aspirate/ear, and 29% of the blood/CSF isolates that they sampled. Interestingly, this 
deletion occurred in 20% of the sputum/tracheal aspirate/ear, and 43% of the blood 
isolates that were sampled. The second sputum isolate that was sequenced did not 
maintain the entire vapXD operon. The significance of this truncation is not yet known, 
however, future studies to determine its effect on survivability and virulence will allow 
investigators to gain insight into the unusual conservation of this in-frame deletion. It 
would be interesting to explore the implications of TA loci in invasive, serum-resistant 
NTHi strains. Normal human serum is bactericidal, but serum-resistant NTHi prevent the 
accumulation of the membrane attack complex (MAC), thus preventing the complement 
system from removing the pathogen. The novel system designed to study the vapC-1 
mutations in cis (Fig. 12 and 13) could be utilized to compare the survivability of NTHi 
expressing either the full length or the truncated VapD toxin gene in the EpiAirway or 
chinchilla models. 
     The genomic location of the TAs based on their flanking one-kilobase regions 
were identical, indicating that all 12 strains shared the genomic organization of at least 
those four regions, which may be important to the conservation of the operons. This 
information continues to support the notion of the necessity for microorganisms to 
maintain TAs to facilitate adaptation to changing environments. Future studies to 
expand the investigation into the organization of the TA loci with regards to a larger 
region in the genome would also be useful for determining any positive or negative 
effects on bacterial survival. While it has been determined that virulent epidemic 
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bacteria have more TA loci than less virulent bacteria (207), a majority of bacterial 
species have between one and five or six to ten type II TA loci (208). NTHi may have 
efficiently reduced its genome to coexist with the host as a commensal, but maintained 
the necessary genes to survive during times of stress. The importance of these TA loci 
to survival and virulence and their high level of conservation provide excellent support 
for the approach of targeting these operons to prevent infections caused by non-b 
serotypes, NTHi strains, and other pathogens that use this mechanism to survive during 




MATERIALS AND METHODS 
Sequencing. Genomic DNA was extracted from all 12 strains using the Thermo 
Scientific GeneJetTM Genomic DNA Purification Kit (Waltham, MA, USA) according to the 
manufacturer’s instructions. Sequencing libraries were prepared from genomic DNA 
using NexteraTM XT DNA Library Preparation Kit (Illumina, San Diego, CA, USA) and 
samples were run separately for sequencing with the MiSeq® 300-cycle micro kit (version 
2) on an IlluminaTM MiSeq platform. Trimming and de novo assembly were completed in 
the Velvet de novo Assembly BaseSpace Labs application (Illumina) against NTHi strain 
86-028NP (NC_007146.2). Automatic annotation was done by Rapid Annotations using 
Subsystems Technology (RAST) v2.0 (209, 210) and the Pathosystems Resource 
Integration Center (PATRIC) (211) (Table 6). Read 1 and Read 2 were combined to 
determine the number of aligned reads. The coverage was calculated with the following 
equation (read length (L) x number of aligned reads (N))/reference sequence genome 
size (bp). The genome size of strain 86-028NP is 1,914,490 bp (169). 
Phylogenetic inference. Twelve clinical isolates sequenced in-house plus an 
additional 27 sequenced typeable and nontypeable strain sequences collected from 
GenBank (169) were used to generate phylogenetic trees using the Codon Trees function 
in PATRIC (184) (Table 10). The Codon Trees function uses amino acid and nucleotide 
sequences from PATRIC’s global Protein Families (PGFams) (184). The protein 
sequences were aligned using multiple sequence comparison by log-expectation 
(MUSCLE) (212), and the nucleotide sequences were aligned using the Codon_align 
function of BioPython (213). Randomized Axelerated Maximum Likelihood (RAxML) was 
used to analyze and describe the protein and nucleotide alignments (214) and rapid 
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bootstrap support values were generated with RAxML software (215). Newick files were 
uploaded to the Interactive Tree of Life (ITOL) (185) to view the final product.  
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These three studies provide insight into the importance of the type II TA loci in 
NTHi. In the first study, the crystal structure of VapBC-1 from NTHi was solved in a 
collaboration with investigators at the University of Kansas. Utilizing this information, 
aspartate-to-asparagine and glutamate-to-glutamine single and double mutations of four 
conserved residues in the PIN domain were constructed. Both the homo- and hetero-
interactions of the mutant VapC-1 toxins in E. coli as well as the mutants’ ability to 
cause growth arrest were quantified. All VapC-1 mutants interacted significantly with 
themselves (homodimerization) and with wild-type VapB-1 (heterodimerization). Only 
one mutant, VapC-1 D99N, caused significant growth arrest in the E. coli assay. The 
vapC-1 mutants were expressed with wild-type vapB-1 under the control of the native 
vapBC-1 promoter in an infection model utilizing primary human epithelial tissues. It was 
determined that a single mutation to the conserved amino acids of the PIN domain 
attenuated NTHi survival in this ex vivo model. Not only were the mutant strains 
attenuated for survival, they also displayed survival numbers that were not significantly 
different from the 86-028NP ΔvapBC-1 knockout that was previously reported (36). 
Another important finding was that additional mutations in VapC-1 were not additive. 
This result will be helpful in efforts to determine a drug target, because it suggests that 
only one small area of the domain needs to be targeted to interfere with ribonuclease 
activity. This study was the first to determine the crystal structure of VapBC-1 from NTHi 
as well as the first to utilize a model to study TA mutant operons in the background of 
NTHi during infections of primary human tissues ex vivo. Promising future steps for this 
project include the utilization of in silico docking to find novel targets to inhibit the 
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ribonuclease activity of the PIN domain during bacterial infections. Once targets are 
determined, these can be characterized in the E. coli growth recovery assay and the 
EpiAirways (Fig. 11 and 13) before advancing to the chinchilla model of experimental 
otitis media. 
The second study designed a growth recovery assay similar to the E. coli model 
(Fig. 11) in the background of NTHi strain R2866 (Fig. 18). The toxin was cloned into a 
targeted delivery vector with the araC regulatory gene and was fused to the PBAD 
promoter to study the induction of vapD in cis in the background of NTHi. E. coli 
arabinose permease genes were targeted into the chromosome of NTHi to determine if 
their presence increased the transport of arabinose across the membrane (Fig. 18). In 
the subsequent growth recovery assay, NTHi did not transport arabinose even with the 
help of on of two E. coli arabinose permeases tested in cis. The assay used in the 
present study was a good demonstration of the molecular techniques that can be 
utilized to study gene expression in NTHi. This study also serves as a reminder that one 
of the difficulties of vaccine construction for NTHi is the genetic heterogeneity among 
the strains. To successfully complete the assay design, multiple strains had to be used 
due to compatibility issues. In future studies, next steps include determining if lack of 
induction was due to insufficient amounts of arabinose transport across the membrane. 
To measure that, a permease could be cloned into an IPTG-inducible plasmid 
compatible in the background of R2866, as it has previously been determined that IPTG 
can cross the membrane of NTHi (146). 
The third study investigated the prevalence and conservation of type II TA 
modules in 12 recently-sequenced NTHi. All 12 strains maintained at least three of the 
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four vap genes that were investigated. Type II TA loci contribute significantly to the 
survival and virulence of NTHi during infections and these loci increase bacterial 
persistence and dormancy following stress. Due to their conservation among strains 
and being essential for bacterial survival during infections, these TA loci are an 
important potential therapeutic target. Unlike other virulence factors such as antibiotic 
resistance genes and protective outer membrane proteins, which can mutate to adapt to 
antimicrobial therapy, it would be deleterious for bacteria to mutate these TA loci. Doing 
so would ultimately hasten cell death under stressful conditions. 
In summary, the lack of newly-identified effective antibiotics increases the need 
to explore other non-standard molecular approaches to treat bacterial infections. Due to 
the conservation of the type II TA loci, these modules prove to be promising candidates 
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